================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
---------
FORM 10-K
---------
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 1998
Commission file number 1-1011
CVS CORPORATION
(Exact name of Registrant as specified in its charter)
--------------------
Delaware 05-0494040
-------- ----------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
One CVS Drive 02895
Woonsocket, Rhode Island -----
------------------------ (Zip Code)
(Address of principal executive offices)
(401) 765-1500
--------------
(Registrant's telephone number, including area code)
Securities registered pursuant to section 12(b) of the Exchange Act:
Name of each exchange
Title of each class on which registered
------------------- --------------------
Common Stock, par value $0.01 per share New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Exchange Act: None
----------------------
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports) and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [ ]
The aggregate market value of the registrant's voting stock* held by
non-affiliates** of the registrant (without admitting that any person whose
shares are not included in this calculation is an affiliate) on March 17, 1999
was approximately $19,895,631,210, based on the closing price on the New York
Stock Exchange.
As of March 17, 1999, the registrant had 390,601,264 shares of common stock
outstanding.
* Does not include 5,224,367 outstanding shares of Series One ESOP
Convertible Preference Stock. As of March 17, 1999, each share of ESOP
Preference Stock was entitled to 2.3 votes per share on all matters
submitted to a vote of the holders of common stock, voting with the common
stock as a single class.
** Only voting stock held by directors and executive officers is excluded.
---------------------------
DOCUMENTS INCORPORATED BY REFERENCE
The following documents (or specified parts thereof) are incorporated by
reference into this Annual Report on Form 10-K as indicated: CVS Corporation's
1998 Annual Report to Shareholders is incorporated by reference into Part II:
Items 5, 6, 7 and 8 and Part IV: Item 14 and CVS Corporation's 1999 Proxy
Statement is incorporated by reference into Part III: Items 10, 11, 12 and 13.
================================================================================
<PAGE>
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Part I Page
----
<S> <C>
Item 1: Business
Overview of CVS' Business.................................................................. 2
Strategic Restructuring Program............................................................ 2
Merger with Revco D.S., Inc................................................................ 3
Merger with Arbor Drugs, Inc............................................................... 3
PharmaCare................................................................................. 3
Relationships with Managed Care Providers.................................................. 4
CVS Stores................................................................................. 4
Store Development.......................................................................... 4
Information Systems........................................................................ 5
Relationships with Suppliers............................................................... 6
Customer Service........................................................................... 6
Government Regulation...................................................................... 6
Competition................................................................................ 7
Cautionary Statement Concerning Forward-Looking Statements................................. 7
Item 2: Properties.................................................................................... 8
Item 3: Legal Proceedings............................................................................. 9
Item 4: Submission of Matters to a Vote of Security Holders........................................... 9
Executive Officers of the Registrant .................................................................... 9
Part II
Item 5: Market for Registrant's Common Equity and Related Stockholder Matters......................... 10
Item 6: Selected Financial Data....................................................................... 10
Item 7: Management's Discussion and Analysis of Financial Condition and Results of Operations......... 10
Item 7A: Quantitative and Qualitative Disclosures About Market Risk.................................... 10
Item 8: Financial Statements and Supplementary Data................................................... 10
Item 9: Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.......... 10
Part III
Item 10: Directors and Executive Officers of the Registrant............................................ 11
Item 11: Executive Compensation........................................................................ 11
Item 12: Security Ownership of Certain Beneficial Owners and Management................................ 11
Item 13: Certain Relationships and Related Transactions................................................ 11
Part IV
Item 14: Exhibits, Financial Statement Schedules, and Reports on Form 8-K.............................. 12
Where You Can Find More Information...................................................................... 15
Independent Auditors' Report............................................................................. 16
Schedule II - Valuation and Qualifying Accounts.......................................................... 17
Signatures .............................................................................................. 18
</TABLE>
1
<PAGE>
PART I
ITEM 1. BUSINESS
<PAGE>
- ------------------------------ -------------------------------------------------
Overview of CVS' CVS Corporation is a leader in the chain drugstore industry
Business in the United States, with revenues of $15.3 billion in
1998. As of December 31, 1998, we were the largest drugstore
chain in the nation in terms of store count, operating 4,122
stores in 24 states in the Northeast, Mid-Atlantic, Midwest
and Southeast regions and in the District of Columbia. Our
stores are well positioned and operate in 66 of the top 100
drugstore markets in the country. We now hold the number one
market share in six of the top ten drugstore markets. We are
also among the industry leaders in terms of store
productivity and operating profit margin.
Pharmacy Operations ~ A primary focus of our operations is
our pharmacy business. In 1998, total pharmacy sales
increased 17.0% to $8.8 billion, representing 58% of total
sales for the year, compared to 55% of total sales in 1997.
As of December 31, 1998, we were the largest drugstore chain
in the nation in terms of prescriptions filled and pharmacy
sales, dispensing over 251 million prescriptions
(approximately 10.5% of the U.S. retail prescription
market). We believe that our pharmacy operations will
continue to represent a critical part of our business and
strategy due to favorable trends. These trends include an
aging American population, greater responsibility being
borne by Americans for their healthcare, an increasing
demand for retail formats that provide easy access and
convenience, discovery of new and better drug therapies and
the need for cost effective healthcare solutions.
Our pharmacy business also benefits from an "independent
file buy" program, in which we purchase prescription files
from independent pharmacies. During 1998, we purchased
approximately 350 prescription files, each containing an
average weekly prescription count of nearly 560. We believe
that independent file buys are productive investments. In
many cases, the independent pharmacist will move to CVS,
thereby providing continuity in the pharmacist-patient
relationship.
Front Store Operations ~ In addition to prescription drugs
and services, we offer a broad selection of general
merchandise, presented in a well-organized fashion, in
stores that are designed to be customer-friendly, inviting
and easy to shop. Merchandise categories include:
over-the-counter drugs, greeting cards, film and
photofinishing services, beauty and cosmetics, seasonal
merchandise and convenience foods. We also offer over 1,400
products under the CVS private label brand, which
represented about 11% of our front store sales in 1998. In
1998, front store sales, which are generally higher margin
than pharmacy sales, increased 3.9% to $6.5 billion,
representing 42% of total sales for the year, compared to
45% of total sales in 1997.
CVS Corporation is a Delaware corporation. Our principal
executive offices are located at One CVS Drive, Woonsocket,
Rhode Island 02895, telephone (401) 765-1500. As of December
31, 1998, CVS and its subsidiaries had about 97,000
employees.
Strategic In November 1997, we completed the final phase of our
Restructuring comprehensive strategic restructuring program, first
Program announced in October 1995 and subsequently refined in May
1996 and June 1997. The strategic restructuring program
included: (i) the sale of Marshalls, Kay-Bee Toys, Wilsons,
This End Up and Bob's Stores, (ii) the spin-off of Footstar,
Inc., which included Meldisco, Footaction and Thom McAn,
(iii) the initial and secondary public offerings of Linens
`n Things and (iv) the elimination of certain corporate
overhead costs.
For more information about our strategic restructuring
program, see Note 4 of "Notes to Consolidated Financial
Statements" on page 30 of our 1998 Annual Report to
Shareholders that is incorporated by reference into Item 8
"Financial Statements and Supplementary Data."
2
<PAGE>
Merger with On May 29, 1997, we completed a merger with Revco D.S. Inc.,
Revco D.S., Inc. pursuant to which 120.6 million shares of CVS common stock
were exchanged for all the outstanding common stock of
Revco. We also converted Revco's stock options into options
to purchase 6.6 million shares of CVS common stock. The
merger of CVS and Revco was a tax-free reorganization that
we treated as a pooling of interests for accounting
purposes. Accordingly, we have restated our historical
consolidated financial statements and footnotes to include
Revco as if it had always been owned by CVS.
The merger with Revco was a milestone event for our company
in that it more than doubled our revenues and made us the
nation's number one drugstore retailer in terms of store
count. The merger brought us into high-growth, contiguous
markets in the Mid-Atlantic, Southeast and Midwest regions
of the United States.
Merger with On March 31, 1998, we completed a merger with Arbor Drugs,
Arbor Drugs, Inc. Inc., pursuant to which 37.8 million shares of CVS common
stock were exchanged for all the outstanding common stock of
Arbor. We also converted Arbor's stock options into options
to purchase 5.3 million shares of CVS common stock. The
merger of CVS and Arbor was also a tax-free reorganization
that we treated as a pooling of interests for accounting
purposes. Accordingly, we have restated our historical
consolidated financial statements and footnotes to include
Arbor as if it had always been owned by CVS.
The merger with Arbor made us the market share leader in
metropolitan Detroit, the nation's fourth largest retail
drugstore market and strengthened our position as the
nation's top drugstore retailer in terms of store count and
retail prescriptions dispensed.
PharmaCare In order to provide patients with the best possible care at
the lowest cost, we follow an integrated healthcare approach
that brings together industry participants such as
physicians, pharmaceutical companies, managed care providers
and pharmacies. Our primary efforts in this area include the
operation and expansion of PharmaCare, our prescription
benefit management subsidiary, and the creation of strategic
alliances with healthcare partners.
PharmaCare provides a full range of prescription benefit
management services to managed care and other organizations.
These services include plan design and administration,
formulary management, mail order pharmacy services, claims
processing and generic substitution. In December 1997,
PharmaCare strengthened its services network by merging with
Revco's prescription benefit management subsidiary, Rx
Connections, and assuming Revco's mail order pharmacy
operations. At the end of 1998, PharmaCare managed
healthcare services for about 6 million people through a
preferred national pharmacy network of over 40,000
pharmacies. In addition, PharmaCare plays an increasing role
in healthcare management through integrated partnerships
with several large managed care providers.
One feature that sets PharmaCare apart from other
prescription benefit management providers is its proprietary
Clinical Information Management System ("CIMS"). CIMS is a
unique communication system that links physicians, patients
and pharmacists to facilitate clinical management. It is a
leading formulary management tool for directing utilization
to the most clinically appropriate and cost-effective
medications. More than 30,000 physicians are currently using
CIMS, which began with only 500 physicians in 1994.
Relationships with The growth in managed care has substantially increased the
Managed Care use of prescription drugs. Managed care providers have (i)
Providers made the cost of prescription drugs more affordable to a
greater number of people and (ii) supported prescription
drug therapy as an alternative to more expensive forms of
treatment, such as surgery. Payments by third party
providers under prescription drug plans represented 84% of
total pharmacy sales in 1998, compared to 81% in 1997.
3
<PAGE>
In a typical third party payment plan, we contract with a
third party payor (such as an insurance company, a
prescription benefit management company, a governmental
agency, a private employer, a health maintenance
organization or other managed care provider) that agrees to
pay for all or a portion of a customer's eligible
prescription purchases in exchange for reduced prescription
rates. Although third party payment plans provide a high
volume of prescription drug sales, these sales typically
generate lower gross margins than other sales due to the
cost containment efforts of third party payors and the
increasing competition among pharmacies for this business.
The cost containment efforts and increased competition has
also caused a continued decline of gross margins on third
party sales. To address this trend, we have dropped a number
of third party programs that fell below our minimum
profitability standards. In the event this trend continues
and we elect to drop additional programs and/or decide not
to participate in future programs that fall below our
minimum profitability standards, we may not be able to
sustain our current rate of sales growth.
CVS Stores We are the nation's largest chain drugstore company based on
store count, operating 4,122 stores in 24 states and the
District of Columbia as of December 31, 1998. The majority
of our existing stores range in size from approximately
8,000 to 10,000 square feet, although most new stores are
based on our 10,125 square foot freestanding prototype,
which typically includes a drive-thru pharmacy.
As of December 31, 1998, 23% of our stores were freestanding
as opposed to being located in strip shopping center sites.
Over 700 CVS stores were operated on an extended hour or
24-hour basis and 900 stores offered one-hour photo service.
We also operated 360 stores with drive-thru pharmacies, and
plan to add over 400 more in 1999. During 1998, we opened
382 new stores, including 198 relocations, and in 1999 we
expect to open approximately 440 new stores, including about
300 relocations. Net selling space for our 4,122 stores was
30.6 million square feet at the end of 1998.
The following is a breakdown by state of the locations of
CVS stores at December 31, 1998:
<TABLE>
<S> <C>
---------------------------------------- ----------------------------------------
Alabama............................144 New Hampshire....................29
Connecticut........................122 New Jersey......................183
Delaware.............................3 New York........................363
District of Columbia................47 North Carolina..................296
Florida.............................22 Ohio............................414
Georgia............................304 Pennsylvania....................319
Illinois............................70 Rhode Island.....................52
Indiana............................291 South Carolina..................196
Kentucky............................71 Tennessee.......................146
Maine...............................20 Vermont...........................2
Maryland...........................170 Virginia........................253
Massachusetts......................321 West Virginia....................59
Michigan..........................225
---------------------------------------- ----------------------------------------
</TABLE>
Store Development The addition of new stores has played, and will continue to
play, a major role in our continued growth. As we open new
stores, we maintain our objective of securing a strong
position in each market that our stores serve. Our strong
market positions provide us with several important
advantages, including (i) an ability to save on advertising
and distribution costs and (ii) an ability to attract
managed care providers, who want to provide their members
with convenient access to pharmacy services.
4
<PAGE>
In addition, we are actively seeking to relocate many of our
strip shopping center locations to freestanding sites. We
expect that relocations of existing shopping center stores
to freestanding locations will account for about two-thirds
of store openings over the next several years. Because of
their more convenient locations and larger size, relocated
stores have typically realized significant improvements in
customer count and revenues, driven largely by increased
sales of higher margin front store merchandise. We believe
our relocation program offers a significant opportunity for
future growth as approximately 23% of our existing stores
are freestanding. We currently expect to have approximately
35% of our stores in freestanding locations by the end of
1999. Our long-term goal is to have 70-80% of our stores
located in freestanding sites. We cannot, however, guarantee
that future store relocations will achieve similar results
as those historically achieved. See "Cautionary Statement
Concerning Forward-Looking Statements" below.
We also have an active remodeling and remerchandising
program which seeks to remodel 20% of our existing stores
and remerchandise another 20% each year. During 1998, we
also completed the process of converting all 1,900 retained
Revco stores into the CVS store format, converted Arbor
stores to CVS' accounting and store systems and closed
Arbor's Troy, Michigan corporate headquarters facility.
We believe that continuing to grow our store base and
locating stores in desirable geographic markets are
essential components to competing effectively in the current
managed care environment. As a result, we believe that our
store development program is an important part of our
ability to maintain our leadership position in the chain
drugstore industry.
Information Systems We have invested significantly in information systems to
enable us to deliver an exceptional level of customer
service while lowering costs and increasing operating
efficiency. Our client-server based systems permit rapid and
flexible system development to meet changing business needs,
while our scaleable technical architecture enables us to
efficiently expand our network to accommodate new stores.
Pharmacy Systems ~ The Rx2000 computer system enables our
pharmacists to fill prescriptions more efficiently, giving
the pharmacists more time to spend with customers. The
system facilitates the management of third party healthcare
plans and enables us to provide managed care providers with
a level of information which we believe is unmatched by our
competitors. By analyzing the data captured by the Rx2000
computer system, we and our managed care partners are able
to evaluate treatment outcomes with an eye toward improving
care and containing costs.
We also continue to make significant progress on our next
generation Rx2000 Pharmacy Delivery System, which will
reengineer the way we fill prescriptions. The project
includes integrated workflow improvements and automated
pill-counting machines in high volume stores.
During 1997, we implemented Rapid Rx Refill, which enables
customers to order prescription refills 24 hours a day using
a touch-tone telephone. In just over 18 months after its
debut, Rapid Rx Refill now accounts for approximately 50% of
refills.
Overall, these initiatives are expected to continue to
enhance pharmacy productivity, lower the costs to fill
prescriptions and improve service by enabling our
pharmacists to spend more time with customers.
5
<PAGE>
Front Store Systems ~ Our point-of-sale scanning technology
has enabled us to develop an advanced retail data warehouse
of information. We use this information to quickly analyze
data on a store-by-store basis to develop targeted marketing
and merchandising strategies. We can also analyze the impact
of pricing, promotion and mix on a category's sales and
profitability, enabling us to develop tactical merchandising
plans for each category by market. We believe that effective
category management increases customer satisfaction and that
our category management approach has been a primary factor
in front store comparable sales gains and improved gross
margins.
We are also beginning the final phase of a multi-year supply
chain initiative which will transform the way we receive,
distribute and sell merchandise. Our supply chain
initiatives will more effectively link our stores and
distribution centers with suppliers to speed the delivery of
merchandise to our stores in a manner that both reduces
out-of-stock positions and lowers our investment in
inventory. The first two phases focused on improving
category management and maximizing gross profit through
price elasticity and promotional allocations. The final
phase will help us to more effectively tailor our product
mix in specific markets. We have already begun to experience
tangible benefits from our supply chain initiatives and we
expect to continue to do so.
Relationships with We centrally purchase most of our merchandise, including
Suppliers prescription drugs, directly from manufacturers. This
purchasing strategy allows us to take advantage of the
promotional and volume discount programs that certain
manufacturers offer to retailers. During 1998, about 85% of
the merchandise purchased by us was received by one of our
distribution centers for redistribution to our stores. The
balance of our store merchandise is shipped directly to our
stores from manufacturers and distributors at prices
negotiated at the corporate level. We believe that the loss
of any one supplier or group of suppliers under common
control would not materially affect our business.
Customer Service We strive to provide the highest levels of service to our
customers and partners. As a result, we devote considerable
time and attention to people, systems and service standards.
We emphasize attracting and training friendly and helpful
associates to work in our stores and throughout our
organization. Each CVS store receives a formal customer
service evaluation twice per year, based on a mystery
shopper program, customer letters and calls, and market
research. Our priority on customer service extends into the
managed care portion of our business as well. In every
market, a Managed Care Service Team ensures that managed
care partners receive high levels of service. Our
pharmacists consistently rank among the best in the industry
on measurements of trust, relationship-building and
accessibility. This high level of service and expertise has
played a key role in the growth of our pharmacy operations.
Government Our pharmacies and pharmacists must be licensed by the
Regulation appropriate state boards of pharmacy. Our pharmacies and
distribution centers are also registered with the Federal
Drug Enforcement Administration. Because of these licensing
and registration requirements, we must comply with various
statutes, rules and regulations, a violation of which could
result in a suspension or revocation of these licenses or
registrations. Under the Omnibus Budget Reconciliation Act
of 1990, our pharmacists are required to offer counseling,
without charge, to customers covered by Medicare about
medication, dosage, delivery system, potential side effects
and other information deemed significant by our pharmacists.
Our pharmacists routinely offer such counseling to all
customers.
We also market products under various trademarks and
tradenames which have been registered in the United States.
Our rights in these trademarks endure for as long as they
are used or registered.
6
<PAGE>
Competition The retail drugstore business is highly competitive. We
believe that we compete principally on the basis of: (i)
store location and convenience, (ii) customer service and
satisfaction, (iii) product selection and variety and (iv)
price. We experience active competition not only from
independent and other chain drugstores, but also from health
maintenance organizations, hospitals, mail order
organizations, supermarkets, discount drugstores and
discount general merchandisers. The deep discount drug
segment has grown significantly over the past several years
as drug chains, and food, discount and specialty retailers
have entered the business. Major retail companies now
operate deep discount drugstores in the most competitive
retailing markets. "Combo" stores, which consist of grocery,
drugstore and several other operations under the same roof,
have also grown significantly over the past several years as
consumers have become more attracted to one-stop shopping.
Retail mass merchandisers with prescription departments have
also grown in popularity.
Cautionary In this report and in the documents incorporated by
Statement Concern- reference (as well as in other public filings, press
ing Forward- releases and oral statements made by Company management), we
Looking Statements make forward-looking statements about future events that
have not yet happened. These statements are subject to risks
and uncertainties. Forward-looking statements include
information concerning:
o our future results of operations, cost savings and
synergies following the Revco and Arbor mergers;
o our ability to elevate the performance level of Revco
stores following the Revco merger;
o our ability to continue to achieve significant sales
growth;
o our belief that we can continue to improve operating
performance by relocating existing in-line stores to
freestanding locations;
o our ability to continue to reduce selling, general and
administrative expenses as a percentage of net sales;
and
o the ability of the Company and our key vendors and
suppliers to successfully manage issues presented by
the Year 2000.
In addition, statements that include the words "believes",
"expects", "anticipates", "intends", "estimates" or similar
expressions are forward-looking statements. For all of these
statements, we claim the protection of the safe harbor for
forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995.
You should understand that the following important factors,
in addition to those discussed elsewhere in this report and
in the documents which are incorporated by reference (and in
our other public filings, press releases and oral statements
made by Company management), could affect the future results
of CVS and could cause those results to differ materially
from those expressed in the forward-looking statements:
What Factors Could Affect the Outcome of Our Forward-Looking
Statements?
Industry and Market Factors
o changes in economic conditions generally or in the
markets served by CVS;
o future federal and/or state regulatory and legislative
actions affecting CVS and/or the chain drugstore
industry;
o consumer preferences and spending patterns;
7
<PAGE>
o competition from other drugstore chains, from
alternative distribution channels such as supermarkets,
membership clubs, mail order companies and internet
companies (e-commerce) and from other third party
plans; and
o the continued efforts of health maintenance
organizations, managed care organizations, pharmacy
benefit management companies and other third party
payors to reduce prescription drug costs.
Operating Factors
o our ability to combine the businesses of CVS, Revco and
Arbor and maintain current operating performance levels
during the integration period(s) and the challenges
inherent in diverting the Company's management focus
and resources from other strategic opportunities and
from operational matters for an extended period of time
during the integration process(es);
o our ability to implement new computer systems and
technologies;
o our ability to continue to secure suitable new store
locations on favorable lease terms as we seek to open
new stores and relocate a portion of our existing store
base to freestanding locations;
o the creditworthiness of the purchasers of former
businesses whose store leases are guaranteed by CVS as
described under Item 2. "Properties" below;
o our ability to continue to purchase inventory on
favorable terms;
o our ability to attract, hire and retain suitable
pharmacists and management personnel;
o our ability to establish effective promotional and
pricing strategies in the different geographic markets
in which we operate; and
o our relationships with suppliers.
ITEM 2. PROPERTIES
We lease most of our stores under long-term leases that vary as to rental
amounts and payments, expiration dates, renewal options and other rental
provisions. We do not think that any individual store lease is significant in
relation to our overall business. For additional information on the amount of
our rental obligations for retail store leases, see Note 6 of "Notes to
Consolidated Financial Statements" on page 30 of our 1998 Annual Report to
Shareholders that is incorporated by reference into Item 8 "Financial Statements
and Supplementary Data."
Our stores are supported by 10 distribution centers located in Rhode Island, New
Jersey, Virginia, Indiana, Alabama, Pennsylvania, Tennessee, North Carolina,
South Carolina and Michigan, which contain an aggregate of approximately
5,400,000 square feet. In addition, we lease additional space near our
distribution centers to handle certain distribution needs.
We own our corporate headquarters, located in three buildings in Woonsocket,
Rhode Island, which contain an aggregate of approximately 345,000 square feet.
Additionally, a fourth headquarters building, expected to contain approximately
207,000 square feet, is currently under construction on a site adjacent to our
existing corporate headquarters. We also lease approximately 352,000 square feet
in seven office buildings in Rhode Island and Massachusetts.
In addition, in connection with certain business dispositions completed between
1991 and 1997, we continue to guarantee lease obligations for approximately
1,600 former stores. We are indemnified for these guarantee obligations by the
respective purchasers. These guarantees generally remain in effect for the
initial lease term and any extension thereof pursuant to a renewal option
provided for in the lease prior to the time of the disposition. Assuming that
each respective purchaser became insolvent, an event which we believe to be
highly unlikely, management estimates that it could settle these obligations for
approximately $1.1 billion as of December 31, 1998.
8
<PAGE>
ITEM 3. LEGAL PROCEEDINGS
From time to time, the Company and its subsidiaries are involved in the
assertion of claims and in litigation incidental to the normal course of
business. In the opinion of management and our independent counsel, we do not
believe that any existing claims or litigation will have a material adverse
effect on our consolidated financial condition, results of operations or future
cash flows.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No matters were submitted to a vote of security holders during the fourth
quarter of the year ended December 31, 1998.
EXECUTIVE OFFICERS OF THE REGISTRANT
The following is an unnumbered Item in Part I of this report.
<TABLE>
<CAPTION>
- --------------------------------------------------------------------------------------------------------------------------
Name and Current Position Five-Year Business History Age
- --------------------------------------------------------------------------------------------------------------------------
<S> <C> <C>
Charles C. Conaway Executive Vice President and Chief Financial Officer of CVS 38
Executive Vice President and Chief Corporation since July 1996; Executive Vice President and Chief
Financial Officer, CVS Corporation and Financial Officer of CVS Pharmacy, Inc. since February 1995; Senior
CVS Pharmacy, Inc. Vice President - Pharmacy of CVS Pharmacy, Inc., September 1992 -
February 1995
- --------------------------------------------------------------------------------------------------------------------------
Stanley P. Goldstein Chairman of the Board of CVS Corporation since January 1987; Chief 64
Chairman of the Board, CVS Corporation Executive Officer of CVS Corporation, October 1996 - May 1998;
President and Chief Executive Officer of Melville Corporation,
January 1987 - October 1996
- --------------------------------------------------------------------------------------------------------------------------
Rosemary Mede Vice President of CVS Corporation and Senior Vice President - Human 52
Vice President, CVS Corporation Resources of CVS Pharmacy, Inc. since October 1997; Vice
Senior Vice President - Human President/General Manager of Business Services, Becton Dickinson &
Resources, CVS Pharmacy, Inc. Co., December 1995 - September 1997; Various management positions
in human resources, Becton Dickinson & Co., 1998 - November 1995
- --------------------------------------------------------------------------------------------------------------------------
Larry J. Merlo Vice President of CVS Corporation since October 1996; Executive 43
Vice President, CVS Corporation Vice President - Stores of CVS Pharmacy, Inc. since March 1998;
Executive Vice President - Stores, CVS Senior Vice President - Stores of CVS Pharmacy, Inc., January 1994
Pharmacy, Inc. - March 1998
- --------------------------------------------------------------------------------------------------------------------------
Daniel C. Nelson Vice President of CVS Corporation since October 1996; Executive 49
Vice President, CVS Corporation Vice President - Marketing of CVS Pharmacy, Inc., since September
Executive Vice President - Marketing, 1993
CVS Pharmacy, Inc.
- --------------------------------------------------------------------------------------------------------------------------
Thomas M. Ryan President and Chief Executive Officer of CVS Corporation since May 46
President and Chief Executive Officer, 1998; Vice Chairman and Chief Operating Officer of CVS Corporation,
CVS Corporation and CVS Pharmacy, Inc. October 1996 - May 1998; President and Chief Executive Officer of
CVS Pharmacy, Inc. since January 1994; Executive Vice President -
Stores of CVS Pharmacy, Inc., January 1990 - January 1994
- --------------------------------------------------------------------------------------------------------------------------
Douglas A. Sgarro Vice President of CVS Corporation and Senior Vice President - 39
Vice President, CVS Corporation Administration and Chief Legal Officer of CVS Pharmacy, Inc. since
Senior Vice President - Administration September 1997; Partner in the New York City office of the law firm
and Chief Legal Officer, CVS Pharmacy, of Brown & Wood LLP, January 1993 - August 1997
Inc.
- --------------------------------------------------------------------------------------------------------------------------
Larry D. Solberg Vice President of CVS Corporation since October 1996; Senior Vice 51
Vice President and Controller, CVS President - Finance and Controller of CVS Pharmacy, Inc. since
Corporation March 1996; Vice President and Controller of CVS Pharmacy, Inc.,
Senior Vice President - Finance and October 1994 - March 1996; Senior Vice President of PIMMS Corp.,
Controller, CVS Pharmacy, Inc. September 1993 - October 1994
- --------------------------------------------------------------------------------------------------------------------------
</TABLE>
In each case, the individual's term of office extends to the date of the board
of directors meeting following the next annual meeting of CVS stockholders. In
addition to the office(s) which they hold in CVS Corporation and CVS Pharmacy,
Inc. as shown above, each of the individuals listed holds various offices in
certain CVS subsidiaries.
9
<PAGE>
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
The information required by this item is included in our 1998 Annual Report to
Shareholders on page 38 under the caption "Quarterly Financial Information," and
is incorporated into this report by reference.
Since October 16, 1996, the common stock of the Company has been listed on the
New York Stock Exchange under the symbol "CVS." As of February 22, 1999, the
record date for the 1999 Annual Meeting of Stockholders, there were 10,500 CVS
stockholders of record. On May 13, 1998, the Company's stockholders approved an
increase in the number of authorized common shares from 300 million to one
billion. Also on that date, the Board of Directors authorized a two-for-one
common stock split, which was effected by the issuance of one additional share
of common stock for each share of common stock outstanding on May 25, 1998. All
share and per share amounts were restated to reflect the effect of the stock
split.
ITEM 6. SELECTED FINANCIAL DATA
The information required by this item is included in our 1998 Annual Report to
Shareholders on page 39 under the caption "Five-Year Financial Summary," and is
incorporated into this report by reference.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
Except for as set forth in the following paragraph, the information required by
this item is included in our 1998 Annual Report to Shareholders on pages 14
through 19 under the caption "Management's Discussion and Analysis of Financial
Condition and Results of Operations," and is incorporated into this report by
reference.
Recent Development:
On February 11, 1999, we sold 5.50% unsecured senior notes due February 15, 2004
in the aggregate principal amount of $300 million in a private placement.
Proceeds from the notes were used to repay outstanding commercial paper.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We have not entered into any transactions using derivative financial instruments
or derivative commodity instruments and we do not believe that there is any
material market risk exposure with respect to other financial instruments (such
as fixed and variable rate borrowings) which would require disclosure under this
Item.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The information required by this item is included in our 1998 Annual Report to
Shareholders on pages 20 through 38, and is incorporated into this report by
reference.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
No events have occurred which would require disclosure under this Item.
10
<PAGE>
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
The information required by this item, with the exception of the information
relating to our executive officers, which is presented in Part I under
"Executive Officers of the Registrant", appears in our 1999 Proxy Statement on
pages 4 through 6 and page 27 under the captions Item 1: "Biographies of our
Board Nominees" and Item 5: "Section 16(a) Beneficial Ownership Reporting
Compliance" and is incorporated into this report by reference.
ITEM 11. EXECUTIVE COMPENSATION
The information required by this item appears in our 1999 Proxy Statement on
pages 7, 8 and 10 through 21 under the captions Item 1: "Director Compensation",
"Compensation Committee Interlocks and Insider Participation", "Compensation
Committee Report on Executive Compensation", "Summary Compensation Table",
"Stock Options", "Stock Performance Graph" and "Certain Executive Arrangements"
and is incorporated into this report by reference.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The information required by this item appears in our 1999 Proxy Statement on
pages 8 through 10 under the captions Item 1: "Share Ownership of Directors and
Certain Executive Officers" and "Share Ownership of Principal Stockholders" and
is incorporated into this report by reference.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
The information required by this item appears in our 1999 Proxy Statement on
page 21 under the caption Item 1: "Transactions with Directors and Officers" and
is incorporated into this report by reference.
11
<PAGE>
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
A. Financial Statements, Schedules and Exhibits
1. Financial Statements
The following appear in our 1998 Annual Report to Shareholders at the pages
indicated below and are incorporated into Part II of this report by reference:
<TABLE>
<CAPTION>
Page
----
<S> <C>
Management's Responsibility for Financial Reporting........................................................... 20
Independent Auditors' Report.................................................................................. 21
Consolidated Statements of Operations for the years ended December 31, 1998, 1997 and 1996.................... 22
Consolidated Balance Sheets as of December 31, 1998 and 1997.................................................. 23
Consolidated Statements of Shareholders' Equity for the years ended December 31, 1998, 1997 and 1996.......... 24
Consolidated Statements of Cash Flows for the years ended December 31, 1998, 1997 and 1996.................... 25
Notes to Consolidated Financial Statements....................................................................26-38
Five-Year Financial Summary....................................................................................39
</TABLE>
2. Schedules
The following schedule appears on page 17 of this report.
Schedule II -- Valuation and Qualifying Accounts
We did not include other financial statement schedules because they are not
applicable or the information is included in the financial statements or related
notes.
3. Exhibits
Exhibits marked with an asterisk (*) are hereby incorporated by reference to
exhibits or appendices previously filed by the Registrant as indicated in
brackets following the description of the exhibit.
<TABLE>
<CAPTION>
Exhibit Description
- ------- -----------
<S> <C>
3.1* Amended and Restated Certificate of Incorporation of the Registrant [incorporated by reference
to Exhibit 3.1 of CVS Corporation's Annual Report on Form
10-K for the fiscal year ended December 31, 1996].
3.1A* Certificate of Amendment to the Amended and Restated Certificate of Incorporation, effective
May 13, 1998 [incorporated by reference to Exhibit 4.1A to
Registrant's Registration Statement No. 333-52055 on Form
S-3/A dated May 18, 1998].
3.2 By-laws of the Registrant, as amended and restated, filed herewith.
4 Pursuant to Regulation S-K, Item 601(b)(4)(iii)(A), no instrument which defines the rights of
holders of long-term debt of the Registrant and its subsidiaries is filed with this report. The
Registrant hereby agrees to furnish a copy of any such
instrument to the Securities and Exchange Commission upon
request.
4.1* Specimen common stock certificate [incorporated by reference to Exhibit 4.1 to the Registration
Statement of the Registrant on Form 8-B dated November 4, 1996].
10.1* Stock Purchase Agreement dated as of October 14, 1995 between The TJX Companies, Inc. and
Melville Corporation, as amended November 17, 1995 [incorporated by reference to Exhibits 2.1
and 2.2 to Melville's Current Report on Form 8-K dated December 4, 1995].
10.2* Stock Purchase Agreement dated as of March 25, 1996 between Melville Corporation and
Consolidated Stores Corporation, as amended May 3, 1996 [incorporated by reference to Exhibits
2.1 and 2.2 to Melville's Current Report on Form 8-K dated May 5, 1996].
12
<PAGE>
Exhibit Description
- ------- -----------
10.3* Distribution Agreement dated as of September 24, 1996 among
Melville Corporation, Footstar, Inc. and Footstar Center,
Inc. [incorporated by reference to Exhibit 99.1 to Melville's
Current Report on Form 8-K dated October 28, 1996].
10.4* Tax Disaffiliation Agreement dated as of September 24, 1996
among Melville Corporation, Footstar, Inc. and certain
subsidiaries named therein [incorporated by reference to
Exhibit 99.2 to Melville's Current Report on Form 8-K dated
October 28, 1996].
10.5* Agreement and Plan of Merger dated as of February 6, 1997, as
amended as of March 19, 1997, among the Registrant, Revco
D.S., Inc. and North Acquisition, Corp. [incorporated by
reference to Annex A to the Registrant's Registration
Statement No. 333-24163 on Form S-4 filed March 28, 1997].
10.6* Agreement and Plan of Merger dated as of February 8, 1998, as
amended as of March 2, 1998, among the Registrant, Arbor
Drugs, Inc. and Red Acquisition, Inc. [incorporated by
reference to Exhibit 2 to the Registrant's Registration
Statement No. 333-47193 on Form S-4 filed March 2, 1998].
10.7* Stockholder Agreement dated as of December 2, 1996 between
the Registrant, Nashua Hollis CVS, Inc. and Linens `n Things,
Inc. [incorporated by reference to Exhibit 10(i)(6) to the
Registrant's Annual Report on Form 10-K for the fiscal year
ended December 31, 1997].
10.8* Tax Disaffiliation Agreement dated as of December 2, 1996
between the Registrant and Linens `n Things, Inc. and certain
of their respective affiliates [incorporated by reference to
Exhibit 10(i)(7) to the Registrant's Annual Report on Form
10-K for the fiscal year ended December 31, 1997].
10.9* Five Year Credit Agreement dated as of May 23, 1997 by and
among the Registrant, the Lenders party thereto, Fleet
National Bank, as Documentation Agent, JP Morgan Securities,
Inc., as Syndication Agent; and The Bank of New York, as
Administrative Agent [incorporated by reference to Exhibit
10(i)(8) to the Registrant's Annual Report on Form 10-K for
the fiscal year ended December 31, 1997].
10.10* Note Purchase Agreement dated June 7, 1989 by and among
Melville Corporation and Subsidiaries Employee Stock
Ownership Plan, as Issuer, Melville Corporation, as
Guarantor, and the Purchasers listed therein [incorporated by
reference to Exhibit 10(i)(9) to the Registrant's Annual
Report on Form 10-K for the fiscal year ended December 31,
1997].
10.11 (i)* 1973 Stock Option Plan [incorporated by reference to
Exhibit (10)(iii)(A)(i) to Melville Corporation's Annual
Report on Form 10-K for the fiscal year ended December 31,
1987].
(ii)* 1987 Stock Option Plan [incorporated by reference to Exhibit
(10)(iii)(A)(iii) to Melville Corporation's Annual Report on
Form 10-K for the fiscal year ended December 31, 1987].
(iii)* 1989 Directors Stock Option Plan [incorporated by reference
to Exhibit B to Melville Corporation's Annual Report on Form
10-K for the fiscal year ended December 31, 1988].
(iv)* Melville Corporation Omnibus Stock Incentive Plan
[incorporated by reference to Exhibit B to Melville
Corporation's Annual Report on Form 10-K for the fiscal year
ended December 31, 1989 and Exhibit A to Melville's
definitive Proxy Statement dated March 7, 1995].
13
<PAGE>
(v)* Profit Incentive Plan of Melville Corporation [incorporated
by reference to Exhibit A to Melville Corporation's
definitive Proxy Statement dated March 14, 1994].
(vi)* Supplemental Retirement Plan for Select Senior Management of
Melville Corporation I as amended through July 1995
[incorporated by reference to Exhibit 10(iii)(A)(vii) to
Melville's Annual Report on Form 10-K for the fiscal year
ended December 31, 1995].
(vii)* Supplemental Retirement Plan for Select Senior Management of
Melville Corporation II as amended through July 1995
[incorporated by reference to Exhibit 10(iii)(A)(viii) to
Melville's Annual Report on Form 10-K for the fiscal year
ended December 31, 1995].
(viii)* Income Continuation Policy for Select Senior Executives of
Melville Corporation as amended through May 12, 1988
[incorporated by reference to Exhibit 10 (viii) to Melville's
Annual Report on Form 10-K for the fiscal year ended December
31, 1994].
(ix)* Melville Corporation 1996 Directors Stock Plan [incorporated
by reference to Exhibit A to Melville's definitive Proxy
Statement dated March 7, 1996].
(x)* Form of Employment Agreements between the Registrant and each
of Messrs. Ryan, Conaway, Nelson and Merlo [incorporated by
reference to the Registrant's Annual Report on Form 10-K/A
for the fiscal year ended December 31, 1996].
(xi)* Deferred Stock Compensation Plan [incorporated by reference
to Exhibit 10(iii)(A)(xi) to the Registrant's Annual Report
on Form 10-K for the fiscal year ended December 31, 1997].
(xii)* 1997 Incentive Compensation Plan [incorporated by reference
to Annex F to Amendment No. 1 to the Registrant's
Registration Statement No. 333-24163 on Form S-4/A filed
April 17, 1997].
(xiii)* Deferred Compensation Plan [incorporated by reference to
Exhibit 10.1 to the Registrant's Quarterly Report on Form
10-Q for the quarter ended June 27, 1998].
(xiv)* Partnership Equity Program [incorporated by reference to
Exhibit 10.2 to the Registrant's Quarterly Report on Form
10-Q for the quarter ended June 27, 1998].
(xv) Form of Collateral Assignment and Executive Life Insurance
Agreement between Registrant and each of Messrs. Ryan,
Conaway, Nelson and Merlo, filed herewith.
11 Computation of Earnings per Common Share [incorporated by
reference to the portion of the 1998 Annual Report to
Shareholders on page 37 under the caption "Reconciliation of
Earnings Per Common Share," which is filed herewith in
Exhibit 13].
13 Portions of the 1998 Annual Report to Shareholders of CVS
Corporation which are specifically designated in this Form
10-K as being incorporated by reference.
21 Subsidiaries of the Registrant.
23 Consent of KPMG LLP.
27 Financial Data Schedule.
</TABLE>
14
<PAGE>
B. Reports on Form 8-K
On February 9, 1999, the Registrant filed a Current Report on Form 8-K in
connection with CVS' announcement that it privately placed $300 million of 5.50%
unsecured senior notes due 2004 as described in Item 7 above.
On February 11, 1999, the Registrant filed a Current Report on Form 8-K in
connection with CVS' announcement that effective April 14, 1999, Stanley P.
Goldstein, Chairman of the Board of Directors, will retire as chairman although
he will remain a Director. In connection with the retirement, Thomas M. Ryan,
currently President and Chief Executive Officer, will be named Chairman of the
Board of Directors and Chief Executive Officer and Charles C. Conaway, currently
Executive Vice President and Chief Financial Officer, will be named President
and Chief Operating Officer.
WHERE YOU CAN FIND MORE INFORMATION
CVS files annual, quarterly and special reports, proxy statements and other
information with the Securities and Exchange Commission ("SEC"). You may read
and copy any reports, statements or other information that we file at the SEC's
public reference rooms in Washington, D.C., New York, New York and Chicago,
Illinois. Please call the SEC at 1-800-SEC-0330 for further information on the
public reference rooms. Our SEC filings are also available to the public from
commercial document retrieval services and at the web site maintained by the SEC
at "http://www.sec.gov."
The SEC allows us to "incorporate by reference", which means that we can
disclose important information to you by referring you to other documents that
we file with the SEC. The information incorporated by reference is legally
considered to be a part of this report.
We incorporate by reference into Part II (Items 5, 6, 7 and 8) and Part IV (Item
14) specified portions of our 1998 Annual Report to Shareholders. We also
incorporate by reference into Part III (Items 10, 11, 12 and 13) specified
portions of our Proxy Statement for the 1999 Annual Meeting of Shareholders,
scheduled to be held on April 14, 1999.
If you are a shareholder, we may have sent you some of the documents
incorporated by reference, but you can obtain any of them through us or the SEC.
Documents incorporated by reference are available from us without charge,
excluding all exhibits unless we have specifically incorporated by reference an
exhibit in this report. Shareholders may obtain documents incorporated by
reference in this report by requesting them in writing or by telephone from:
CVS Corporation
Investor Relations
670 White Plains Road - Suite 210
Scarsdale, NY 10583
Telephone: (800) 201-0938
15
<PAGE>
INDEPENDENT AUDITORS' REPORT
Board of Directors and Shareholders
CVS Corporation:
Under date of January 27, 1999, we reported on the consolidated balance
sheets of CVS Corporation and subsidiaries as of December 31, 1998 and 1997, and
related consolidated statements of operations, shareholders' equity and cash
flows for each of the years in the three-year period ended December 31, 1998, as
contained in the 1998 Annual Report to Shareholders. These consolidated
financial statements and our report thereon are incorporated by reference in the
annual report on Form 10-K for the fiscal year ended 1998. In connection with
our audits of the aforementioned consolidated financial statements, we also
audited the consolidated financial statement schedule as listed in the
accompanying index. This financial statement schedule is the responsibility of
the Company's management. Our responsibility is to express an opinion on this
financial statement schedule based on our audits.
In our opinion, such financial statement schedule, when considered in
relation to the basic consolidated financial statements taken as a whole,
presents fairly, in all material respects, the information set forth therein.
/s/ KPMG LLP
- ------------
KPMG LLP
Providence, Rhode Island
January 27, 1999
16
<PAGE>
CVS CORPORATION
Schedule II -- Valuation and Qualifying Accounts
<TABLE>
<CAPTION>
- -------------------------------------------------------------------------------------------------------------------------
Balance at Additions Deductions
Beginning of Charged to Charged to Balance at
In millions Year Profit & Loss Reserve(1) End of Year
- -------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Accounts Receivable Allowance for Doubtful Accounts:
Year Ended December 31, 1998 $ 39.2 $ 6.3 $ 5.7 $ 39.8
- -------------------------------------------------------------------------------------------------------------------------
Year Ended December 31, 1997 36.9 7.9 5.6 39.2
- -------------------------------------------------------------------------------------------------------------------------
Year Ended December 31, 1996 59.3 11.6 34.0 36.9
- -------------------------------------------------------------------------------------------------------------------------
</TABLE>
(1) 1996 includes a deduction of $21.2 million that relates to the actual
write-off of certain receivables of former operating businesses that were
retained by the Company subsequent to the sale of the related operating
businesses.
17
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this Annual Report on Form
10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
CVS CORPORATION
Date: March 25, 1999 By: /s/ CHARLES C. CONAWAY
-----------------------
Charles C. Conaway
Executive Vice President and
Chief Financial Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
<TABLE>
<CAPTION>
Signature Title(s) Date
---------
<S> <C> <C>
/s/ THOMAS M. RYAN President, Chief Executive Officer March 25, 1999
- --------------------------------- and Director (Principal Executive
Thomas M. Ryan Officer)
/s/ CHARLES C. CONAWAY Executive Vice President and Chief
- ----------------------------- Financial Officer (Principal March 25, 1999
Charles C. Conaway Financial Officer)
/s/ LARRY D. SOLBERG Vice President and Controller March 25, 1999
- --------------------------------- (Principal Accounting Officer)
Larry D. Solberg
/s/ EUGENE APPLEBAUM Director March 25, 1999
- ------------------------------
Eugene Applebaum
/s/ ALLAN J. BLOOSTEIN Director March 25, 1999
- --------------------------------
Allan J. Bloostein
/s/ W. DON CORNWELL Director March 25, 1999
- --------------------------------
W. Don Cornwell
/s/ THOMAS P. GERRITY Director March 25, 1999
- -------------------------------
Thomas P. Gerrity
/s/ STANLEY P. GOLDSTEIN Chairman of the Board and Director March 25, 1999
- -----------------------------
Stanley P. Goldstein
/s/ WILLIAM H. JOYCE Director March 25, 1999
- --------------------------------
William H. Joyce
/s/ TERRY R. LAUTENBACH Director March 25, 1999
- --------------------------
Terry R. Lautenbach
/s/ TERRENCE MURRAY Director March 25, 1999
- -----------------------------
Terrence Murray
/s/ SHELI Z. ROSENBERG Director March 25, 1999
- -------------------------------
Sheli Z. Rosenberg
/s/ IVAN G. SEIDENBERG Director March 25, 1999
- ------------------------------
Ivan G. Seidenberg
/s/ THOMAS O. THORSEN Director March 25, 1999
- -----------------------------
Thomas O. Thorsen
</TABLE>
18
<PAGE>
EXHIBIT INDEX
3.2 By-Laws of the Registrant, as amended and restated [Filed
electronically with SEC only].
10.11(xv) Form of Collateral Assignment and Executive Life Insurance Agreement
between Registrant and each of Messrs. Ryan, Conaway, Nelson and
Merlo [Filed electronically with SEC only].
13 Portions of the 1998 Annual Report to Shareholders of CVS
Corporation which are specifically designated in this Form 10-K as
being incorporated by reference. [Filed electronically with SEC
only].
21 List of Subsidiaries of the Registrant.
23 Consent of Independent Auditors.
27 Financial Data Schedule [Filed electronically with SEC only].
19
BY-LAWS
OF
CVS CORPORATION
(as amended through January 12, 1999)
-------------------
ARTICLE I
STOCKHOLDERS
Section 1. ANNUAL MEETING. The annual meeting of the stockholders of the
corporation, for the purpose of electing directors and for the transaction of
such other business as may be brought before the meeting, shall be held at the
principal office of the corporation, or at such other place within or without
the State of Delaware stated in the notice of the meeting as the Board of
Directors may determine, on such day in the month of April or May as the Board
of Directors may determine, at 10:00 o'clock in the forenoon, Rhode Island time,
or at such other hour stated in the notice of the meeting as the Board of
Directors may determine.
Section 2. SPECIAL MEETINGS. Special meetings of stockholders may be called
by the Board of Directors, the Chairman of the Board of Directors or the Chief
Executive Officer and may not be called by any other person.
Special meetings shall be held at such place within or without the State of
Delaware as is specified in the call thereof.
Section 3. NOTICE OF MEETING; WAIVER. Unless otherwise required by statute,
the notice of every meeting of the stockholders shall be in writing and signed
by the Chairman of the Board of Directors or the Chief Executive Officer (or the
President or a Vice President or the Secretary or an Assistant Secretary, in
each case acting at the direction of the Chairman or the Chief Executive
Officer) and shall state the time when and the place where it is to be held, and
a copy thereof shall be served, either personally or by mail, upon each
stockholder of record entitled to vote at such meeting, not less than ten nor
more than sixty days before the meeting. If the meeting to be held is other than
the annual meeting of stockholders, the notice shall also state the purpose or
purposes for which the meeting is called and shall indicate that it is being
issued by or at the direction of the person or persons calling the meeting. If,
at any meeting, action is proposed to be taken which would, if taken, entitle
stockholders to receive payment for their shares pursuant to Section 262 of the
General Corporation Law of the State of Delaware, the notice of such meeting
shall include a statement of that purpose and to that effect. If the notice is
mailed, it shall be directed to a stockholder at the stockholder's address as it
appears on the record of stockholders unless the stockholder shall have filed
with the Secretary of the corporation a written request that notices intended
for the stockholder be
<PAGE>
mailed to some other address, in which case it shall be mailed to the address
designated in such request.
Notice of a meeting need not be given to any stockholder who submits a
signed waiver of notice, in person or by proxy, whether before or after the
meeting. The attendance of a stockholder at a meeting, in person or by proxy,
without protesting prior to the conclusion of the meeting the lack of notice of
such meeting, shall constitute a waiver of notice by the stockholder.
Section 4. QUORUM. At any meeting of the stockholders the holders of a
majority of the shares entitled to vote and being present in person or
represented by proxy shall constitute a quorum for all purposes, unless the
representation of a different number shall be required by law or by another
provision of these by-laws, and in that case the representation of the number so
required shall constitute a quorum.
If the holders of the amount of shares necessary to constitute a quorum
shall fail to attend in person or by proxy, the holders of a majority of the
shares present in person or represented by proxy at the meeting may adjourn from
time to time without further notice other than by an announcement made at the
meeting. At any such adjourned meeting at which a quorum is present, any
business may be transacted which might have been transacted at the meeting as
originally called.
Section 5. ORGANIZATION. The Chairman of the Board of Directors or, in his
absence, the Chief Executive Officer or, in his absence, the President, any
Executive Vice President, Senior Vice President or Vice President in the order
of their seniority or in such other order as may be designated by the Board of
Directors, shall call meetings of the stockholders to order and shall act as
chairman of such meetings. The Board of Directors or the Executive Committee may
appoint any stockholder to act as chairman of any meeting in the absence of any
of such officers and in the event of such absence and the failure of such board
or committee to appoint a chairman, the stockholders present at such meeting may
nominate and appoint any stockholder to act as chairman.
The Secretary of the corporation, or, in his absence, an Assistant
Secretary, shall act as secretary of all meetings of stockholders, but, in the
absence of said officers, the chairman of the meeting may appoint any person to
act as secretary of the meeting.
Section 6. VOTING. At each meeting of the stockholders every stockholder of
record having the right to vote shall be entitled to vote either in person or by
proxy.
Section 7. ACTION BY WRITTEN CONSENT. Any action required or permitted to
be taken at any annual or special meeting of stockholders may be taken without a
meeting on written consent, setting forth the action so taken, signed by the
holders of all outstanding shares entitled to vote thereon. Written consent thus
given by the holders of all outstanding shares entitled to vote shall have the
same effect as a unanimous vote of the stockholders.
2
<PAGE>
Section 8. INSPECTORS OF ELECTION. The Board of Directors, in advance of
any stockholders' meeting, may appoint one or more Inspectors of Election to act
at the meeting or any adjournment thereof. If Inspectors are not so appointed,
the person presiding at a stockholders' meeting may, and on the request of any
stockholder entitled to vote thereat, shall appoint one or more inspectors. In
case any person appointed fails to appear or act, the vacancy may be filled by
appointment made by the Board in advance of the meeting or at the meeting by the
person presiding thereat. Inspectors shall be sworn.
Section 9. CONDUCT OF ELECTION. At each meeting of the stockholders, votes,
proxies, consents and ballots shall be received, and all questions touching the
qualification of voters, the validity of proxies and the acceptance or rejection
of votes, shall be decided by the Inspectors of Election.
ARTICLE II
BOARD OF DIRECTORS
Section 1. NUMBER OF DIRECTORS. The number of directors of the corporation
shall be not less than three nor more than eighteen, as determined by action of
the Board of Directors.
Section 2. TERM AND VACANCIES. Directors shall be elected at the annual
meeting of stockholders to hold office until the next annual meeting and until
their respective successors have been duly elected and have qualified.
Vacancies in the Board of Directors occurring between annual meetings, from
any cause whatsoever including vacancies created by an increase in the number of
directors, shall be filled by the vote of a majority of the remaining directors,
though less than a quorum.
Directors need not be stockholders.
Section 3. GENERAL POWERS OF DIRECTORS. The business of the corporation
shall be managed under the direction of its Board of Directors subject to the
restrictions imposed by law, by the corporation's certificate of incorporation
and amendments thereto, or by these by-laws.
Section 4. MEETINGS OF DIRECTORS. The directors may hold their meetings and
may keep an office and maintain the books of the corporation, except as
otherwise provided by statute, in such place or places in the State of Delaware
or outside the State of Delaware as the Board may, from time to time, determine.
Any action required or permitted to be taken by the Board of Directors may
be taken without a meeting if all of the directors consent in writing to the
adoption of a
3
<PAGE>
resolution authorizing the action, and in such event the resolution and the
written consent of all directors thereto shall be filed with the minutes of the
proceedings of the Board of Directors.
Any one or more directors may participate in a meeting of the Board of
Directors by means of a conference telephone or similar communications equipment
allowing all persons participating in the meeting to hear each other at the same
time, and participation by such means shall constitute presence in person at a
meeting.
Section 5. REGULAR MEETINGS. Regular meetings of the Board of Directors
shall be held at the principal office of the corporation in the County of
Providence, Town of Woonsocket, State of Rhode Island, or at such other place
within or without the State of Delaware as shall be designated in the notice of
the meeting as follows: One meeting shall be held immediately following the
annual meeting of stockholders and further meetings shall be held at such
intervals or on such dates as may from time to time be fixed by the directors,
all of which meetings shall be held upon not less than four days' notice served
upon each director by mailing such notice to the director at the director's
address as the same appears upon the records of the corporation, except the
meeting which shall be held immediately following the annual meeting of
stockholders which meeting shall be held without notice.
Section 6. SPECIAL MEETINGS. Special meetings of the Board of Directors
shall be held whenever called by the direction of the Chairman of the Board of
Directors, or of the Chief Executive Officer of the corporation, or of one-third
of the directors at the time in office. The Secretary shall give notice of each
special meeting by mailing such notice not less than four days, or by
telegraphing or telecopying such notice not less than two days, before the date
set for a special meeting, to each director.
Section 7. WAIVER. Notice of a meeting need not be given to any director
who submits a signed waiver of notice whether before or after the meeting, or
who attends the meeting without protesting, prior thereto or at its
commencement, the lack of notice to him.
Section 8. QUORUM. One-third of the total number of directors shall
constitute a quorum for the transaction of business, but if at any meeting of
the Board there be less than a quorum present, the majority of those present may
adjourn the meeting from time to time.
Section 9. ORDER OF BUSINESS. At meetings of the Board of Directors
business shall be transacted in such order as the Board may fix and determine.
At all meetings of the Board of Directors, the Chairman of the Board of
Directors, or in his absence, the Chief Executive Officer, or in the absence of
both, the President, any Executive Vice President or any Vice President
(provided such person be a member of the Board) shall preside.
4
<PAGE>
Section 10. ELECTION OF CHAIRMAN, OFFICERS AND COMMITTEES. At the first
regular meeting of the Board of Directors in each year, at which a quorum shall
be present, held next after the annual meeting of the stockholders, the Board of
Directors shall proceed to the election of the executive officers of the
corporation (including the Chairman of the Board), and of the Executive
Committee, if the Board of Directors shall provide for such committee under the
provisions of Article III hereof.
The Board of Directors from time to time may fill any vacancies among the
executive officers, members of the Executive Committee and members of other
committees, and may appoint additional executive officers and additional members
of such Executive Committee or other committees.
Section 11. COMPENSATION. Directors who are not officers or employees of
the corporation or any of its subsidiaries may receive such remuneration as the
Board may fix, in addition to a fixed sum for attendance at each regular or
special meeting of the Board or a Committee of the Board; provided, however,
that nothing herein contained shall be construed to preclude any director from
serving the corporation in any other capacity or receiving compensation
therefor. In addition, each director shall be entitled to reimbursement for
expenses incurred in attending any meeting of the Board or Committee thereof.
ARTICLE III
COMMITTEES
Section 1. EXECUTIVE COMMITTEE. The Board of Directors by resolution
adopted by a majority of the entire Board, may designate from the Directors an
Executive Committee consisting of three or more, to serve at the pleasure of the
Board. At all times when the Board of Directors is not in session, the Executive
Committee so designated shall have and exercise the powers of the Board of
Directors, except that such committee shall have no authority as to the matters
set out in Section 3 of this Article III.
Meetings of the Executive Committee shall be called by any member of the
same, on three days' mailed notice, or one day's telegraphed or telecopied
notice to each of the other members, stating therein the purpose for which such
meeting is to be held. Notice of meeting may be waived, in writing, by any
member of the Executive Committee.
All action by the Executive Committee shall be recorded in its minutes and
reported from time to time to the Board of Directors.
The Executive Committee shall fix its own rules of procedure and shall meet
where and as provided by such rules or by resolution of the Board of Directors.
5
<PAGE>
Any action required or permitted to be taken by the Executive Committee may
be taken without a meeting if all of the members of the Executive Committee
consent in writing to the adoption of a resolution authorizing the action, and
in such event the resolution and the written consent of all members of the
Executive Committee thereto shall be filed with the minutes of the proceedings
of the Executive Committee.
Any one or more members of the Executive Committee may participate in a
meeting of the Executive Committee by means of a conference telephone or similar
communications equipment allowing all persons participating in the meeting to
hear each other at the same time, and participation by such means shall
constitute presence in person at a meeting.
Section 2. OTHER COMMITTEES. The Board of Directors may appoint such other
committees, of three or more, as the Board shall, from time to time, deem
advisable, which committees shall have and may exercise such powers as shall be
prescribed, from time to time, by resolution of the Board of Directors, except
that such committees shall have no authority as to the matters set out in
Section 3 hereof.
Actions and recommendations by each committee which shall be appointed
pursuant to this section shall be recorded and reported from time to time to the
Board of Directors.
Each such committee shall fix its own rules of procedure and shall meet
where and as provided by such rules or by resolution of the Board of Directors.
Any action required or permitted to be taken by any such committee may be
taken without a meeting if all of the members of such committee consent in
writing to the adoption of a resolution authorizing the action, and in such
event the resolution and the written consent of all members of such committee
thereto shall be filed with the minutes of the proceedings of such committee.
Any one or more members of any such committee may participate in a meeting
of such committee by means of a conference telephone or similar communications
equipment allowing all persons participating in the meeting to hear each other
at the same time, and participation by such means shall constitute presence in
person at a meeting.
Section 3. LIMITATIONS. No committee shall have authority as to the
following matters:
(1) The submission to stockholders of any action that needs stockholders'
authorization.
(2) The filling of vacancies in the Board of Directors or in any committee.
6
<PAGE>
(3) The fixing of compensation of the directors for serving on the Board or
on any committee.
(4) The amendment or repeal of the by-laws, or the adoption of new by-laws.
(5) The amendment or repeal of any resolution of the Board which by its
terms shall not be so amendable or repealable.
Section 4. ALTERNATES. The Board may designate one or more directors as
alternate members of any such committees, who may replace any absent member or
members at any meeting of such committees.
Section 5. COMPENSATION. Members of special or standing committees may
receive such salary for their services as the Board of Directors may determine;
provided, however, that nothing herein contained shall be construed to preclude
any member of any such committee from serving the corporation in any other
capacity or receiving compensation therefor.
ARTICLE IV
OFFICERS
Section 1. TITLES AND TERMS OF OFFICE. The executive officers of the
corporation shall be a Chairman of the Board of Directors, a Chief Executive
Officer and a President, each of whom shall be a member of the Board of
Directors, such number of Executive Vice Presidents, Senior Vice Presidents and
Vice Presidents as the Board of Directors shall determine, and a Controller, a
Treasurer and a Secretary, all of whom shall be chosen by the Board of
Directors.
The Board of Directors may also appoint one or more Assistant Secretaries
and one or more Assistant Treasurers, and such other junior officers as it shall
deem necessary, who shall have such authority and shall perform such duties as
from time to time may be prescribed by the Board of Directors.
Any two or more offices except President and Vice President may be held by
the same person.
The officers of the corporation shall each hold office for one year and
until their successors are chosen and qualified, and shall be subject to removal
at any time by the affirmative vote of the majority of the entire Board of
Directors.
Section 2. CHAIRMAN OF THE BOARD. The Board of Directors shall designate a
Chairman of the Board (or one or more Co-Chairmen of the Board). The Chairman of
the Board shall preside over the meetings of the Board of Directors and of the
stockholders at which he will be present. If there be more than one, the
Co-Chairmen
7
<PAGE>
designated by the Board of Directors will perform such duties. The Chairman or
Chairmen of the Board shall perform such other duties as may be assigned to him
or them by the Board of Directors.
Section 3. CHIEF EXECUTIVE OFFICER. The Chief Executive Officer of the
corporation shall have general management and control over the policy, business
and affairs of the corporation and shall have such other authority and perform
such other duties as usually appertain to a chief executive officer of a
business corporation. He shall exercise the powers of the Chairman of the Board
of Directors during his absence or inability to act.
Section 4. PRESIDENT. The President, if any, shall have such authority and
shall perform such duties as the Board of Directors, the Executive Committee, or
the Chief Executive Officer may from time to time determine.
Section 5. EXECUTIVE VICE PRESIDENTS, SENIOR VICE PRESIDENTS AND VICE
PRESIDENTS. The Executive Vice Presidents, Senior Vice Presidents and Vice
Presidents, if any, shall be designated and shall have such powers and perform
such duties as may be assigned to them by the Board of Directors, the Executive
Committee, the Chief Executive Officer or the President. They shall, in order of
their seniority or in such other order as may be designated by the Board of
Directors, the Executive Committee, the Chief Executive Officer or the
President, exercise the powers of the Chief Executive Officer during the absence
or inability to act of the Chief Executive Officer and the President.
Section 6. CHIEF FINANCIAL OFFICER. A Chief Financial Officer or other
officer designated by the Board of Directors shall be the principal financial
officer of the corporation. He shall render to the Board of Directors, whenever
the Board may require, an account of the financial condition of the corporation,
and shall do and perform such other duties as from time to time may be assigned
to him by the Board of Directors, the Executive Committee, the Chief Executive
Officer or the President.
Section 7. CONTROLLER. A Controller or other officer designated by the
Board of Directors shall be the principal accounting officer of the corporation
and, subject to the direction of the Chief Financial Officer, he shall have
supervision over all the accounts and account books of the corporation. He shall
have such other powers and perform such other duties as from time to time may be
assigned to him by the Chief Financial Officer, and shall exercise the powers of
the Chief Financial Officer during his absence or inability to act.
Section 8. TREASURER. The Treasurer shall have custody of the funds and
securities of the corporation which come into his hands. When necessary or
proper, he may endorse on behalf of the corporation for collection, checks,
notes, and other instruments and obligations and shall deposit the same to the
credit of the corporation in such bank or banks or depositories as the Board of
Directors or the Executive Committee
8
<PAGE>
shall designate; whenever required by the Board of Directors or the Executive
Committee, he shall render a statement of his cash account; he shall keep, or
cause to be kept, books of account, in which shall be entered and kept full and
accurate accounts of all monies received and paid out on account of the
corporation; he shall perform all acts incident to the position of Treasurer,
subject to the control of the Board of Directors, the Executive Committee, the
Chief Executive Officer, the President and the Chief Financial Officer; he shall
give bond for the faithful discharge of his duties, if, as, and when the Board
of Directors or the Executive Committee may require. He shall perform such other
duties as from time to time may be assigned to him by the Board of Directors,
the Executive Committee, the Chief Executive Officer, the President or the Chief
Financial Officer.
Section 9. ASSISTANT TREASURER. Each Assistant Treasurer shall have such
powers and perform such duties as may be delegated to him, and the Assistant
Treasurers shall, in the order of their seniority, or in such other order as may
be designated by the Board of Directors, the Executive Committee, the Chief
Executive Officer, the President or the Chief Financial Officer, exercise the
powers of the Treasurer during his absence or inability to act.
Section 10. SECRETARY. The Secretary shall keep the minutes of all meetings
of the Board of Directors and the minutes of all meetings of the stockholders
and of the Executive Committee, in books provided for that purpose; he shall
attend to the giving and serving of all notices of the corporation; and he shall
have charge of the certificate books, transfer books and records of stockholders
and such other books and records as the Board of Directors or Executive
Committee may direct, all of which shall at all reasonable times be open to the
inspection of any director upon application during the usual business hours.
He shall keep at the office of the corporation, or at the office of the
transfer agent or registrar of the corporation's capital stock, a record
containing the names, alphabetically arranged, of all persons who are
stockholders of the corporation, showing their places of residence, the number
of shares held by them, respectively, the time when they respectively became the
owners thereof, and the amount paid thereon, and such record shall be open for
inspection as prescribed by Section 220 of the General Corporate Law of the
State of Delaware. He shall in general perform all the duties incident to the
office of Secretary, subject to the control of the Board of Directors, the
Executive Committee, the Chairman of the Board of Directors, the Chief Executive
Officer and the President.
Section 11. ASSISTANT SECRETARIES. Each Assistant Secretary shall have such
powers and perform such duties as may be delegated to him, and the Assistant
Secretaries shall, in the order of their seniority, or in such other order as
may be designated by the Board of Directors, the Executive Committee, the
Chairman of the Board of Directors, the Chief Executive Officer or the
President, exercise the powers of the Secretary during his absence or inability
to act.
9
<PAGE>
Section 12. VOTING UPON STOCKS. Unless otherwise ordered by the Board of
Directors or by the Executive Committee, the Chief Executive Officer of the
corporation, or one designated in a proxy executed by him, and in the absence of
either, the President, or a person designated in a proxy executed by him, and in
the absence of all such, the Executive Vice Presidents, Senior Vice Presidents
or the Vice Presidents of the corporation, in the order of their seniority,
shall have full power and authority on behalf of the corporation to attend, and
to act, and to vote at meetings of stockholders of any corporation in which this
corporation may hold stock, and each such officer of the corporation shall have
power to sign a proxy deputizing others to vote the same; and all such who shall
be so authorized to vote shall possess and may exercise any and all rights and
powers incident to the ownership of such stock and which, as the owner thereof,
the corporation might have possessed and exercised, if present.
The Board of Directors or the Executive Committee may, by resolution from
time to time, confer like powers on any other person or persons which shall
supersede the powers of those designated in the foregoing paragraph.
Section 13. EXECUTION OF CHECKS, ETC. All checks, notes, drafts or other
instruments for the payment of money shall be signed on behalf of this
corporation by such person or persons and in such manner as the Board of
Directors or Executive Committee may prescribe by resolution from time to time.
ARTICLE V
STOCK; RECORD DATE
Section 1. CERTIFICATES FOR STOCK. The certificates for shares of the stock
of the corporation shall be in such form as shall be proper or approved by the
Board of Directors. Each certificate shall state (i) that the corporation is
formed under the laws of the State of Delaware, (ii) the name of the person or
persons to whom issued, (iii) the number and class of shares and the designation
of the series, if any, which such certificate represents and (iv) the par value,
if any, of each share represented by such certificate. Each certificate shall be
signed by the Chairman of the Board of Directors, the President, an Executive
Vice President or a Vice President, and also by the Treasurer or an Assistant
Treasurer or the Secretary or an Assistant Secretary and sealed with the
corporation's seal; provided, however, that if such certificates are signed by a
transfer agent or transfer clerk and by a registrar the signature of the
Chairman of the Board of Directors, the President, an Executive Vice President,
Vice President, Treasurer, Assistant Treasurer, Secretary and Assistant
Secretary and the seal of the corporation upon such certificates may be
facsimiles, engraved or printed.
Section 2. TRANSFER OF SHARES. Shares of the stock of the corporation
may be transferred on the record of stockholders of the corporation by the
holder thereof in
10
<PAGE>
person or by his duly authorized attorney upon surrender of a certificate
therefor properly endorsed.
Section 3. AUTHORITY FOR ADDITIONAL RULES REGARDING TRANSFER. The Board of
Directors and the Executive Committee shall have power and authority to make all
such rules and regulations as respectively they may deem expedient concerning
the issue, transfer and registration of such certificates for shares of the
stock of the corporation as well as for the issuance of new certificates in lieu
of those which may be lost or destroyed, and may require of any stockholder
requesting replacement of lost or destroyed certificates, bond in such amount
and in such form as they may deem expedient to indemnify the corporation, and/or
the transfer agents, and/or the registrars of its stock against any claims
arising in connection therewith.
Section 4. TRANSFER AGENTS AND REGISTRARS. The Board of Directors or
Executive Committee may appoint one or more transfer agents and one or more
registrars of transfer and may require all stock certificates to be
countersigned by such transfer agent and registered by such registrar of
transfers. One person or organization may serve as both transfer agent and
registrar.
Section 5. RECORD DATE. For the purpose of determining the stockholders
entitled to notice of or to vote at any meeting of stockholders or any
adjournment thereof, or to express consent to or dissent from any proposal
without a meeting, or for the purpose of determining stockholders entitled to
receive payment of any dividend or the allotment of any rights, or for the
purpose of any other action, the Board of Directors shall fix in advance a date
as the record date for any such determination of stockholders. Such date shall
not be more than sixty nor less than ten days before the date of such meeting,
nor more than sixty days prior to any other action.
Section 6. LIST OF STOCKHOLDERS AS OF RECORD DATE. The Secretary of the
corporation or the transfer agent of its stock shall make and certify a list of
the stockholders as of the record date and number of shares of each class of
stock of record in the name of each stockholder and such list shall be present
at every meeting of stockholders. If the right to vote at any meeting is
challenged, the inspectors of elections, or person presiding thereat, shall
require such list of stockholders to be produced as evidence of the right of the
persons challenged to vote at such meeting, and all persons who appear from such
list to be stockholders entitled to vote thereat, may vote at such meeting.
Section 7. DIVIDENDS. Dividends may be declared and paid out of the surplus
of the corporation as often and at such times and to such extent as the Board of
Directors may determine, consistent with the provisions of the certificate of
incorporation of the corporation.
11
<PAGE>
ARTICLE VI
CORPORATE SEAL
The Board of Directors shall provide a suitable seal containing the
name of the corporation and of the state under the laws of which the corporation
was incorporated; and the Secretary shall have the custody thereof.
ARTICLE VII
AMENDMENTS
These by-laws or any of them, may be altered, amended or repealed, or
new by-laws may be made by the stockholders entitled to vote thereon at any
annual or special meeting thereof or by the Board of Directors.
COLLATERAL ASSIGNMENT AGREEMENT
This AGREEMENT made the _______ day of ________________, 19____, by and between
CVS CORPORATION, a Rhode Island corporation (hereinafter "the corporation" and
______________ (hereinafter "The Employee").
WHEREAS, the Employee is currently a valued employee of the Employer and the
Employer wishes to assist the Employee with his/her personal life insurance
program and the Employee desires to accept such assistance:
NOW, THEREFORE, in consideration of the mutual covenants contained herein, it is
agreed between the parties as follows:
Part I - Individual Life Insurance Agreement
--------------------------------------------
1. Application for Insurance. The Employee will apply to Metropolitan Life
Insurance Company (hereinafter called "the Insurer") for a policy of
life insurance of his/her life that provides a death benefit during
active employment equal to four times annual salary, capped at $2
million and that provides for a post-retirement death benefit equal to
two times final salary, capped at $2 million. The death benefit shall
be adjusted periodically to reflect changes in the Employee's coverage
amount.
2. Ownership of Insurance. The Employee shall be the owner of the Policy
and the Employee may exercise all rights of ownership with respect to
the policy except as otherwise provided in this Agreement.
3. Payment of Premiums on Policy. The total premium cost of the Plan is
paid by CVS Corporation.
4. Employee's Obligation to Corporation. The Employee shall be obligated
to repay to the Corporation the aggregate amount which the Corporation
pays on behalf of the Employee under Section 3 of this Agreement. This
obligation of the Employee to the Corporation shall be payable as
provided in Section 8 and 10 of this Agreement.
5. Collateral Assignment of Policy. Part II of this Agreement provides for
an assignment of the Policy (hereinafter "the Collateral Assignment")
to the Corporation to secure the Employee's obligation under Section 4.
6. Surrender of Termination of Policy. While this Agreement is in force
and effect, the Employee will not sell, surrender or terminate the
Policy without the Corporation's consent.
7. Assignment of Employee's Interest. In the Event the Employee transfers
his/her rights in the Policy (other than rights assigned to the
Corporation pursuant to this Agreement), then all of the Employee's
rights in the Policy and this Agreement shall pass to his/her
transferee (subject to the terms of this Agreement), and the Employee
shall have no further rights in the Policy or this Agreement.
<PAGE>
COLLATERAL ASSIGNMENT AGREEMENT
8. Death Claims
(a) If the Employee dies while this Agreement is in effect, the
beneficiary or beneficiaries named by the Employee shall be
entitled to receive a death benefit equal to four times annual
salary, capped at $2 million. If the employee dies after
retirement, the Employee's beneficiary or beneficiaries shall
be entitled to receive a death benefit equal to two times
final salary, capped at $2 million (in either cash reduced by
an amount paid by the Corporation under Section 4).
(b) If the Employee dies while this Agreement is in effect, the
Corporation shall be entitled to receive the amount of death
benefits provided under the Policy in excess of the amount
payable to the Employee's beneficiaries under paragraph (a) of
this Section 8. The Employee understands that the amount
received by the Corporation under this paragraph (b) may be
less than or exceed the amount which the Corporation paid on
behalf of the Employee under Section 3 of this Agreement. The
receipt of this amount by the Corporation shall satisfy the
Employee's obligations under Section 4 of this Agreement.
9. Termination of Agreement. This Agreement shall be terminated on the
occurrence of any of the following events:
(a) The Employee's retirement from the Corporation, or, if later
fifteen years from the date of issuance of the Policy.
(b) The Employee's termination of the employment from the Corporation
(c) Either party's submission of written notice to the other party, of
intent to terminate Part I of this Agreement.
(d) The discontinuance by the Corporation, for any reason, of premium
payments required under Section 3 of this Agreement.
10. Disposition of Policy on Termination of Agreement. If this Agreement is
terminated under Section 9 of this Agreement, then the Employee shall
have thirty days in which to repay the Corporation the aggregate
amounts paid by the Corporation under Section 3 above. However, the
Employee's obligation to repay the Corporation shall not exceed the
cash surrender value of the policy at the time this Agreement is
terminated. Upon payment in full by the Employee, the Corporation
shall execute all documents required by the Insurer to release the
Collateral Assignment of the Policy. If the Employee does not repay
such amounts, the Corporation may enforce any rights which it has
under the Collateral Assignment of the Policy.
11. Insurance Company Not a Party The Insurer:
(a) shall not be deemed to be a party to this Agreement for any
purpose nor be in any way responsible for its validity; and
(b) shall have no liability except as set forth in the Policy and in
any assignment of the Policy filed with it.
<PAGE>
COLLATERAL ASSIGNMENT AGREEMENT
Part II - Assignment of Life Insurance Policy as Collateral
-----------------------------------------------------------
1. In return for the premium payments made by the Corporation as set forth in
Section 3 of Part I hereof, the Employee hereby assigns to the Corporation,
its successors and assigns, the Policy issued by the Insurer upon the life
of the Employee and all rights thereunder (except as provided in Section 3
of Part II below), subject to all the terms and conditions of the policy
and to all superior liens, if any, which the Insurer may have against the
Policy.
2. The Employee and the Corporation agree that the following specific rights
are included in this Agreement and Collateral Assignment:
(a) The sole right to collect from the Insurer the net proceeds of the
Policy when it becomes a claim by death or maturity;
(b) The sole right to surrender the Policy and receive the surrender value
thereof at any time provided by the terms of the Policy and at such
other times as the Insurer may allow; and
(c) The sole right to collect and receive all distributions made under the
Policy, and to exercise any and all options contained in the Policy
with respect to the distributions; unless and until the Corporation
notifies the Insurer in writing to the contrary, the distributions or
shares of surplus, dividend deposits and additions shall continue on
the Policy in force at the time of this assignment; and
(d) The sole right to direct investment allocations under the policy
3. It is agreed that the following specific rights, so long as the Policy has
not been surrendered, are reserved and excluded from this Agreement and
Collateral Assignment.
(a) The right to designate any change in beneficiary; and
(b) The right to elect any optional form of settlement permitted by the
Policy or allowed by the Insurer.
Any designation or change of beneficiary or election of a form of settlement
shall be made subject to this Agreement and Collateral Assignment and to the
rights of the Corporation under this Agreement.
4. This Collateral Assignment is made and the Policy is to be held as
collateral security for any and all liabilities of the Employee to the
Corporation arising under this Agreement.
5. The corporation covenants and agrees with the Employee as follows:
(a) That the Corporation will not exercise the right to surrender the
Policy until there has been a failure to repay the Corporation the
aggregate amounts paid by the Corporation under Section 3 of Part I of
this Agreement within the thirty day period described in Section 10 of
Part I of this Agreement; and
(b) That the Corporation will, upon request, forward without unreasonable
delay to the Insurer the Policy for endorsement of any designation or
change of beneficiary or any election of any optional form of
settlement.
6. The Employee declares that no proceedings in bankruptcy are pending against
him/her and that his/her property is not subject to any assignment for the
benefit of creditor.
<PAGE>
`COLLATERAL ASSIGNMENT AGREEMENT
Provisions Applicable to Parts I and II
---------------------------------------
A. Amendment of Agreement. This Agreement shall not be modified or amended
except by a writing signed by the Corporation and the Employee. This
Agreement shall be binding upon the heirs, administrators or executors and
the successors and assigns to each party to this Agreement.
B. State Law. This Agreement shall be subject to and shall be construed under
the laws of Rhode Island.
CVS CORPORATION
By: _________________________
Title: _________________________
EMPLOYEE:
__________________________________
TRUSTEE (if applicable):
__________________________________
Management's Discussion and Analysis of Financial Condition and Results of
Operations
We strongly recommend that you read our audited consolidated financial
statements and footnotes found on pages 22 through 38 of this Annual Report
along with this important discussion and analysis.
- --------------------------------------------------------------------------------
Bar Graph:
1998 1997 1996
Net Sales (In billions) ($15.3, $13.7, $11.8)
Operating Profit Percentage* (6.2%, 5.7%, 5.1%)
Diluted Earning Per Share** ($1.26, $1.05, $0.78)
- --------------------------------------------------------------------------------
* Percent of net sales before non-recurring charges and gain.
** Earnings from continuing operations before non-recurring charges and gains.
Introduction
1998 was an excellent year for CVS. We are pleased to report that despite the
significant challenges our company faced in integrating the operations of Arbor
Drugs, Inc. and Revco D.S., Inc., we achieved another record year in terms of
net sales, operating profit and diluted earnings per share, excluding the effect
of the non-recurring charges and gain.
Our strong performance in 1998 translated into a 72.7% return to our
shareholders. This compares to a total return of 18.1% for the Dow Jones
Industrial Average and 28.6% for the S&P 500. While we are extremely proud of
this accomplishment, we cannot guarantee that our future performance will result
in similar returns to shareholders. Our total market capitalization grew to more
than $21 billion at December 31, 1998.
As a result of the significant increase in our stock price, on May 13, 1998, the
Board of Directors approved a two-for-one common stock split, effective June 15,
1998. At that time, the Board also approved an increase in our annual post-split
cash dividend to $0.23 per share, underscoring their continued optimism in our
prospects for future growth.
Mergers
As you review our consolidated financial statements and footnotes, you should
carefully consider the impact of the following merger transactions and the
non-recurring charges that we recorded:
CVS/Arbor Merger
On March 31, 1998, we completed a merger with Arbor pursuant to which 37.8
million shares of CVS common stock were exchanged for all of the outstanding
common stock of Arbor. We also converted Arbor's stock options into options to
purchase 5.3 million shares of our common stock. The merger of CVS and Arbor was
a tax-free reorganization, which we treated as a pooling of interests under
Accounting Principles Board Opinion No. 16, "Business Combinations."
Accordingly, we have restated our historical consolidated financial statements
and footnotes to include Arbor as if it had always been owned by CVS.
The merger with Arbor made us the market share leader in metropolitan Detroit,
the nation's fourth largest retail drugstore market, and strengthened our
position as the nation's top drugstore retailer in terms of store count and
retail prescriptions dispensed. We believe that we can achieve cost savings from
the combined operations of approximately $30 million annually. This will come
primarily from closing Arbor's corporate headquarters, achieving economies of
scale in advertising, distribution and other operational areas, and spreading
our investment in information technology over a larger store base. Please read
the "Cautionary Statement Concerning Forward-Looking Statements" section below.
CVS/Revco Merger
On May 29, 1997, we completed a merger with Revco pursuant to which 120.6
million shares of CVS common stock were exchanged for all of the outstanding
common stock of Revco. We also converted Revco's stock options into options to
purchase 6.6 million shares of our common stock. The merger of CVS and Revco was
also a tax-free reorganization that we treated as a pooling of interests.
Accordingly, we have restated our historical consolidated financial statements
and footnotes to include Revco as if it had always been owned by CVS.
The merger with Revco was a milestone event for our company in that it more than
doubled our revenues and made us the nation's number one drugstore retailer in
terms of store count. The merger brought us into high-growth, contiguous markets
in the Mid-Atlantic, Southeast and Midwest regions of the United States.
14
<PAGE>
Merger Charges
During the second quarter of 1998, we recorded a $158.3 million charge to
operating expenses for direct and other merger-related costs pertaining to the
CVS/Arbor merger transaction and related restructuring activities. At that time,
we also recorded a $10.0 million charge to cost of goods sold to reflect
markdowns on non-compatible Arbor merchandise.
During the second quarter of 1997, we recorded a $411.7 million charge to
operating expenses for direct and other merger-related costs pertaining to the
CVS/Revco merger transaction and related restructuring activities. At that time,
we also recorded a $75.0 million charge to cost of goods sold to reflect
markdowns on non-compatible Revco merchandise.
Integration Update
We are pleased to report that the integration of Arbor is well underway. We have
already converted Arbor to CVS' accounting and store systems and closed the
Troy, Michigan corporate headquarters facility. With respect to merger
synergies, we achieved approximately $20 million of cost savings in 1998 and we
believe we are on track to realize at least $30 million of cost savings in 1999
from the Arbor merger. Please read the "Cautionary Statement Concerning Forward
Looking Statements" section below. We are further pleased to report that the
integration of Revco is now complete and we have accomplished our goal of
achieving at least $100 million of annual cost savings from the Revco merger.
Where You Can Find More Information About
the Mergers
Please read the "Results of Operations" and "Cautionary Statement Concerning
Forward-Looking Statements" sections below and Notes 2 and 3 to the consolidated
financial statements for other important information about the mergers and the
non-recurring charges that we recorded.
Results of Operations
Net sales increased 11.1% in 1998 to $15.3 billion. This compares to increases
of 16.2% in 1997 and 12.5% in 1996. Same store sales, consisting of sales from
stores that have been open for more than one year, rose 10.8% in 1998, 9.7% in
1997 and 8.9% in 1996. Pharmacy same store sales increased 16.5% in 1998, 16.5%
in 1997 and 13.5% in 1996. Our pharmacy sales as a percentage of total sales
were 58% in 1998, 55% in 1997 and 52% in 1996. Our third party prescription
sales as a percentage of total pharmacy sales were 84% in 1998, 81% in 1997 and
80% in 1996.
As you review our sales performance, we believe you should consider the
following important information:
o Our pharmacy sales growth continued to benefit from our ability to attract
and retain managed care customers, our ongoing program of purchasing
prescription files from independent pharmacies and favorable industry trends.
These trends include an aging American population; many "baby boomers" are
now in their fifties and are consuming a greater number of prescription
drugs. The increased use of pharmaceuticals as the first line of defense for
healthcare and the introduction of a number of successful new prescription
drugs also contributed to the growing demand for pharmacy services.
o Our front store sales growth was driven by solid performance in categories
such as cosmetics, private label, seasonal, vitamins/nutrition, greeting
cards, skin care, film and photofinishing, and convenience foods.
o The increase in net sales in 1998 was positively affected by our efforts to
improve the performance of the Revco stores. To do this, we converted the
retained Revco stores to the CVS store format and relocated certain stores.
We are pleased to report that we are seeing improvements, especially in front
store sales. However, the improved performance has been aided by temporary
promotional events and the rate of progress has varied and, we expect it to
continue to vary, on a market-by-market basis.
o The increase in net sales in 1997 was positively affected by our acquisition
of Big B, Inc., effective November 16, 1996. Excluding the positive impact of
the Big B acquisition, net sales increased 11.3% in 1997 when compared to
1996. Please read Notes 2 and 3 to the consolidated financial statements for
other important information about the Big B acquisition.
o We have an active program in place to relocate our existing shopping center
stores to larger, more convenient, freestanding locations. Historically, we
have achieved significant improvements in customer count and net sales when
we do this. The resulting increase in net sales has typically been driven by
an increase in front store sales, which normally have a higher gross margin.
We believe that our relocation program offers a significant opportunity for
future growth, as 23% of our existing stores are freestanding. We currently
expect to have 35% of our stores in freestanding locations by the end of
1999. Our long-term goal is to have 70-80% of our stores located in
freestanding sites. We cannot, however, guarantee that future store
relocations will deliver the same results as those historically achieved.
Please read the "Cautionary Statement Concerning Forward-Looking Statements"
section below.
15
<PAGE>
Gross margin as a percentage of net sales was 27.0% in 1998. This compares to
27.0% in 1997 and 27.9% in 1996. As you review our gross margin performance,
please remember to consider the impact of the $10.0 million charge we recorded
in 1998 to reflect markdowns on non-compatible Arbor merchandise and the $75.0
million charge we recorded in 1997 to reflect markdowns on non-compatible Revco
merchandise. If you exclude the effect of these non-recurring charges, our
comparable gross margin as a percentage of net sales was 27.1% in 1998, 27.6% in
1997 and 27.9% in 1996.
Why has our comparable gross margin rate been declining?
o Pharmacy sales are growing at a faster pace than front store sales. On
average, our gross margin on pharmacy sales is lower than our gross margin on
front store sales.
o Sales to customers covered by third party insurance programs have continued
to increase and, thus, have become a larger part of our total pharmacy
business. Our gross margin on third party sales has continued to decline
largely due to the efforts of managed care organizations and other pharmacy
benefit managers to reduce prescription drug costs. To address this trend, we
have dropped a number of third party programs that fell below our minimum
profitability standards. In the event this trend continues and we elect to
drop additional programs and/or decide not to participate in future programs
that fall below our minimum profitability standards, we may not be able to
sustain our current rate of sales growth.
Total operating expenses were 22.0% of net sales in 1998. This compares to 25.1%
in 1997 and 22.9% in 1996. As you review our performance in this area, please
remember to consider the impact of the following non-recurring charges:
o During 1998, we recorded the $158.3 million charge associated with the Arbor
merger.
o During 1997, we recorded the $411.7 million charge associated with the Revco
merger. We also recorded a $31.0 million charge for certain costs associated
with the restructuring of Big B. Please read Note 3 to the consolidated
financial statements for other important information about this charge.
o During 1996, we recorded a $12.8 million charge when Rite Aid Corporation
announced that it had withdrawn its tender offer to acquire Revco. This event
took place before we merged with Revco.
If you exclude the effect of these non-recurring charges, comparable total
operating expenses as a percentage of net sales were 20.9% in 1998, 21.9% in
1997 and 22.8% in 1996.
What have we done to improve our comparable total operating expenses as a
percentage of net sales?
o We eliminated most of Arbor's existing corporate overhead in 1998 and most of
Revco's in 1997.
o Our strong sales performance has consistently allowed our net sales to grow
at a faster pace than total operating expenses.
o Our information technology initiatives have led to greater productivity,
which has resulted in lower operating costs and improved sales. Our major IT
initiatives include: Supply Chain Management, Rx2000 Pharmacy Delivery
Project, and Rapid Refill.
As a result of combining the operations of CVS, Arbor and Revco, we were able to
achieve substantial annual operating cost savings in 1998 and 1997. Although we
are extremely proud of this accomplishment, we strongly advise you not to rely
on the resulting operating expense improvement trend to predict our future
performance.
Operating profit increased $510.8 million to $772.2 million in 1998. This
compares to $261.4 million in 1997 and $591.9 million in 1996. If you exclude
the effect of the non-recurring charges we recorded in gross margin and in total
operating expenses, our comparable operating profit increased $161.4 million (or
20.7%) to $940.5 million in 1998. This compares to $779.1 million in 1997 and
$604.7 million in 1996. Comparable operating profit as a percentage of net sales
was 6.2% in 1998, 5.7% in 1997 and 5.1% in 1996.
Other expense (income), net consisted of the following for the years ended
December 31:
<TABLE>
<CAPTION>
- -----------------------------------------------------------
In millions 1998 1997 1996
- -----------------------------------------------------------
<S> <C> <C> <C>
Gain on sale of securities $ -- $ -- $(121.4)
Dividend income -- -- (5.6)
Interest expense 69.7 59.1 84.7
Interest income (8.8) (15.0) (9.2)
- -----------------------------------------------------------
Other expense (income), net $ 60.9 $ 44.1 $ (51.5)
- -----------------------------------------------------------
</TABLE>
During 1998, our other expense (income), net increased $16.8 million due to
higher interest expense and lower interest income. Our interest expense
increased because we maintained higher average borrowing levels during 1998 to
finance, in part, additional inventory. You should be aware that we purchased
the additional inventory to support several initiatives. First we converted the
Revco stores to the CVS merchandise mix. We also held promotional name change
events in most Revco markets and realigned our stores and distribution centers.
In order to properly support these important initiatives, we decided to
temporarily increase our inventory levels during
16
<PAGE>
1998. We believe that our inventory levels were back to "normal" at December 31,
1998.
During 1997, our other expense (income), net increased $95.6 million to a net
other expense of $44.1 million from a net other income of $51.5 million in 1996.
As you review this change, you should consider the impact of the following
information:
o During 1997, we recognized interest income on a note receivable that we
received when we sold Kay-Bee Toys in 1996. This note was sold in 1997. We
also had lower interest expense in 1997 because we retired most of the higher
interest rate debt we absorbed as part of the CVS/Revco Merger.
o During 1996, we recognized a $121.4 million gain when we sold certain equity
securities that we received when we sold Marshalls in 1995.
Income tax provision - Our effective income tax rate was 44.3% in 1998. This
compares to 64.8% in 1997 and 42.1% in 1996. Our effective income tax rates were
higher in 1998 and 1997 because certain components of the charges we recorded in
conjunction with the CVS/Arbor and CVS/Revco merger transactions were not
deductible for income tax purposes.
Earnings from continuing operations before extraordinary item increased $319.9
million to $396.4 million (or $0.98 per diluted share) in 1998. This compares to
$76.5 million (or $0.16 per diluted share) in 1997 and $372.4 million (or $0.95
per diluted share) in 1996. If you exclude the effect of the non-recurring
charges we recorded in cost of goods sold and total operating expenses and the
gain on sale of securities included in other expense (income), net, our
comparable earnings from continuing operations before extraordinary item
increased 21.7% to $510.1 million (or $1.26 per diluted share) in 1998. This
compares to $419.2 million (or $1.05 per diluted share) in 1997 and $306.8
million (or $0.78 per diluted share) in 1996.
Discontinued Operations - In November 1997, we completed the final phase of a
comprehensive strategic restructuring program, under which we sold Marshalls,
Kay-Bee Toys, Wilsons, This End Up and Bob's Stores. As part of this program, we
also completed the spin-off of Footstar, Inc., which included Meldisco,
Footaction and Thom McAn, completed the initial and secondary public offerings
of Linens `n Things and eliminated certain corporate overhead costs. As part of
completing this program, we recorded an after-tax charge of $20.7 million during
the second quarter of 1997 and $148.1 million during the second quarter of 1996
to finalize our original liability estimates. Please read Note 4 to the
consolidated financial statements for other important information about this
program.
Extraordinary item - During the second quarter of 1997, we retired $865.7
million of the debt we absorbed when we acquired Revco. As a result, we recorded
a charge for an extraordinary item, net of income taxes, of $17.1 million. The
extraordinary item included the early retirement premiums we paid and the
balance of our deferred financing costs.
Net earnings were $396.4 million (or $0.98 per diluted share) in 1998. This
compares to $76.9 million (or $0.16 per diluted share) in 1997 and $208.2
million (or $0.52 per diluted share) in 1996.
Liquidity & Capital Resources
Liquidity ~ The Company has three primary sources of liquidity: cash provided by
operations, commercial paper and uncommitted lines of credit. Our commercial
paper program is supported by a $670 million, five-year unsecured revolving
credit facility that expires on May 30, 2002 and a $460 million, 364 day
unsecured revolving credit facility that expires on June 26, 1999. Our credit
facilities contain customary financial and operating covenants. We believe that
the restrictions contained in these covenants do not materially affect our
financial or operating flexibility. We can also obtain up to $35 million of
short-term financing through various uncommitted lines of credit. As of December
31, 1998, we had $736.6 million of commercial paper outstanding at a weighted
average interest rate of 5.8% and $34.5 million outstanding under our
uncommitted lines of credit at a weighted average interest rate of 4.8%.
Capital Resources ~ With a total debt to capitalization ratio of 25.4% at
December 31, 1998, we are pleased to report that our financial condition
remained strong at year-end. Although there can be no assurance and assuming
market interest rates remain favorable, we currently believe that we will
continue to have access to capital at attractive interest rates in 1999. We
further believe that our cash on hand and cash provided by operations, together
with our ability to obtain additional short-term and long-term financing, will
be sufficient to cover our future working capital needs, capital expenditures
and debt service requirements. Please read the "Cautionary Statement Concerning
Forward-Looking Statements" section below.
Capital Expenditures
Our capital expenditures totaled $502.3 million in 1998. This compares to $341.6
million in 1997 and $328.9 million in 1996. During 1998, we opened 184 new
stores, relocated 198 existing stores and closed 156 stores. During 1999, we
expect that our capital expenditures will total approximately $450-$500 million.
This currently includes a plan to open 140 new stores, relocate 300 existing
stores and close 130 stores. As of December 31, 1998, we operated 4,122 stores
in 24 states and the District of Columbia. This compares to 4,094 stores as of
December 31, 1997.
17
<PAGE>
Goodwill
In connection with various acquisitions which were accounted for as purchase
transactions, we recorded goodwill, which represented the excess of the purchase
price we paid over the fair value of the net assets we acquired. The goodwill we
recorded in these transactions is being amortized on a straight-line basis,
generally over periods of 40 years.
We evaluate goodwill for impairment whenever events or changes in circumstances
suggest that the carrying amount may not be recoverable. Under these conditions,
we would compare our estimated future cash flows to our carrying amounts. If our
carrying amounts exceeded our expected future cash flows, we would consider the
goodwill to be impaired and we would record an impairment loss. We do not
currently believe that any of our goodwill is impaired.
Recent Accounting Pronouncements
In March 1998, the American Institute of Certified Public Accountants issued
Statement of Position 98-1, "Accounting for the Costs of Computer Software
Developed or Obtained for Internal Use," effective for fiscal years beginning
after December 15, 1998. This statement defines which costs incurred to develop
or purchase internal-use software should be capitalized and which costs should
be expensed. We are in the process of determining what impact, if any, this
pronouncement will have on our consolidated financial statements.
In June 1998, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards No. 133, "Accounting for Derivative Instruments
and Hedging Activities." This statement requires companies to record derivative
instruments on their balance sheet at fair value and establishes new accounting
practices for hedge instruments. This statement is effective for years beginning
after June 15, 1999. We are in the process of determining what impact, if any,
this pronouncement will have on our consolidated financial statements.
Discriminatory Pricing Litigation Against Drug Manufacturers and Wholesalers
The Company is a party to two lawsuits which have been filed against various
pharmaceutical manufacturers and wholesalers:
o The first lawsuit is a class action that alleges that manufacturers and
wholesalers conspired to fix and/or stabilize the price of the prescription
drugs sold to retail pharmacies in violation of the Sherman Antitrust Act. In
this lawsuit, CVS is a member of the plaintiff class.
o The second lawsuit was filed by individual chain pharmacies, including Revco,
as plaintiffs. This lawsuit alleges unlawful price discrimination against
retail pharmacies by manufacturers and wholesalers in violation of the
Robinson-Patman Act, and asserts a conspiracy in violation of the Sherman
Act. CVS became a party to this lawsuit when it acquired Revco.
With respect to the first lawsuit, fifteen defendants have agreed to settlements
totaling $720 million. The class plaintiffs were not able to reach settlements
with the four remaining defendants. As a result, a trial of the claims was
commenced in September 1998. The trial resulted in a directed verdict in favor
of the remaining defendents. The court has yet to approve a formula for
distributing the settlement proceeds to class members. While we believe that our
portion of the distribution could be significant, we can not predict an exact
dollar amount at this time.
With respect to the second lawsuit, a few settlements have been reached to date
and the case is expected to go to trial in the latter part of 1999. Our portion
of any settlement or judgment in this lawsuit could also be significant, but we
can not predict an exact dollar amount at this time.
Year 2000 Compliance Statement
The "Year 2000 Issue" relates to the inability of certain computer hardware and
software to properly recognize and process date-sensitive information for the
Year 2000 and beyond. Without corrective measures, our computer applications
could fail and/or produce erroneous results. To address this concern, we have a
work plan in place to identify the potential issues that could affect our
business. The following discussion will provide you with an update on where we
stand on this important matter.
Information Technology ("IT") Systems - We have completed the assessment phase
for each of our critical information technology systems. Our IT business systems
include point-of-sale, Rx2000 pharmacy, supply chain management, financial
accounting and other corporate office systems. To date, we have modified or
replaced approximately 85% of our critical IT business systems. We currently
expect to modify or replace the remaining critical business systems by the end
of the second quarter of 1999 and complete our systems testing by the end of the
third quarter of 1999.
Non-IT Systems - We are currently in the process of completing the assessment
phase for each of our critical non-IT business systems, including those with
embedded chip technology. Our non-IT business systems include distribution
center logistics, HVAC, energy management, facility alarms and key entry
systems. To date, we have modified or replaced approximately 30% of our critical
non-IT business systems. We currently expect to modify or replace the remaining
critical
18
<PAGE>
non-IT business systems and complete our systems testing by the end of the third
quarter of 1999.
Business Partners - As part of our project work plan, we have been communicating
with our key business partners, including our vendors, suppliers, financial
institutions, managed care organizations, pharmacy benefit managers, third party
insurance programs and governmental agencies to determine the status of their
Year 2000 compliance programs. Although there can be no assurance that we will
not be adversely affected by the Year 2000 issues of our business partners, we
believe that ongoing communication will continue to minimize our risk.
Potential Risks - The potential risks associated with failing to remediate our
Year 2000 issues include: temporary disruptions in store operations; temporary
disruptions in the ordering, receiving and shipping of merchandise and in the
ordering and receiving of other goods and services; temporary disruptions in the
billing and collecting of accounts receivable; temporary disruptions in services
provided by banks and other financial institutions; temporary disruptions in
communication services; and temporary disruptions in utility services.
Incremental Cost -We currently estimate that the incremental cost associated
with completing our Year 2000 work plan will be approximately $10 million, about
half of which had been incurred through December 31, 1998. This estimate could
change as additional information becomes available. The cost to resolve our Year
2000 issues will be funded through our operating cash flows.
Contingency Plan - We are currently in the process of developing a contingency
plan for each area in our organization that could be affected by the Year 2000
issue. Although we currently anticipate minimal business disruption, the failure
of either the Company or one or more of our major business partners to remediate
critical Year 2000 issues could have a materially adverse impact on our
business, operations and financial condition. Please read the "Cautionary
Statement Concerning Forward Looking Statements" section below.
Cautionary Statement Concerning Forward-Looking Statements
We have made forward-looking statements in this Annual Report that are subject
to risks and uncertainties. For these statements, we claim the protection of the
safe harbor for forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. We strongly recommend that you become familiar
with the specific risks and uncertainties that we have outlined for you under
the caption "Cautionary Statement Concerning Forward-Looking Statements" in our
Annual Report on Form 10-K for the year ended December 31, 1998.
19
<PAGE>
Management's Responsibility for Financial Reporting
The integrity and objectivity of the financial statements and related financial
information in this Annual Report are the responsibility of the management of
the Company. The financial statements have been prepared in conformity with
generally accepted accounting principles and include, when necessary, the best
estimates and judgments of management.
The Company maintains a system of internal controls designed to provide
reasonable assurance, at appropriate cost, that assets are safeguarded,
transactions are executed in accordance with management's authorization, and the
accounting records provide a reliable basis for the preparation of the financial
statements. The system of internal accounting controls is continually reviewed
by management and improved and modified as necessary in response to changing
business conditions and the recommendations of the Company's internal auditors
and independent auditors.
KPMG LLP, independent auditors, are engaged to render an opinion regarding the
fair presentation of the consolidated financial statements of the Company. Their
accompanying report is based upon an audit conducted in accordance with
generally accepted auditing standards and included a review of the system of
internal controls to the extent they considered necessary to support their
opinion.
The Audit Committee of the Board of Directors, consisting solely of outside
directors, meets periodically with management, internal auditors and the
independent auditors to review matters relating to the Company's financial
reporting, the adequacy of internal accounting controls and the scope and
results of audit work. The internal auditors and independent auditors have free
access to the Audit Committee.
/s/ Thomas M. Ryan
- ------------------
Thomas M. Ryan
President and Chief Executive Officer
/s/ Charles C. Conaway
- ----------------------
Charles C. Conaway
Executive Vice President and Chief Financial Officer
January 27, 1999
20
<PAGE>
Independent Auditors' Report
[LOGO: KPMG LOGO]
Board of Directors and Shareholders
CVS Corporation:
We have audited the accompanying consolidated balance sheets of CVS Corporation
and subsidiaries as of December 31, 1998 and 1997, and the related consolidated
statements of operations, shareholders' equity, and cash flows for each of the
years in the three year period ended December 31, 1998. These consolidated
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these consolidated financial
statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the financial position of CVS Corporation and
subsidiaries as of December 31, 1998 and 1997, and the results of their
operations and their cash flows for each of the years in the three year period
ended December 31, 1998, in conformity with generally accepted accounting
principles.
/s/ KPMG LLP
- ------------
KPMG LLP
Providence, Rhode Island
January 27, 1999
21
<PAGE>
Consolidated Statements of Operations
<TABLE>
<CAPTION>
====================================================================================================================
Years Ended December 31,
In millions, except per share amounts 1998 1997 1996
- --------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Net sales $15,273.6 $13,749.6 $11,831.6
Cost of goods sold, buying and warehousing costs 11,144.4 10,031.3 8,530.7
- --------------------------------------------------------------------------------------------------------------------
Gross margin 4,129.2 3,718.3 3,300.9
Selling, general and administrative expenses 2,949.0 2,776.0 2,490.8
Depreciation and amortization 249.7 238.2 205.4
Merger, restructuring and other non-recurring charges 158.3 442.7 12.8
- --------------------------------------------------------------------------------------------------------------------
Total operating expenses 3,357.0 3,456.9 2,709.0
- --------------------------------------------------------------------------------------------------------------------
Operating profit 772.2 261.4 591.9
Gain on sale of securities -- -- (121.4)
Dividend income -- -- (5.6)
Interest expense, net 60.9 44.1 75.5
- --------------------------------------------------------------------------------------------------------------------
Other expense (income), net 60.9 44.1 (51.5)
- --------------------------------------------------------------------------------------------------------------------
Earnings from continuing operations before income taxes and extraordinary item 711.3 217.3 643.4
Income tax provision (314.9) (140.8) (271.0)
- --------------------------------------------------------------------------------------------------------------------
Earnings from continuing operations before extraordinary item 396.4 76.5 372.4
Discontinued operations:
Loss from operations, net of tax benefit of $31.0 -- -- (54.8)
Gain (loss) on disposal, net of tax provision (benefit) of $12.4, and $(56.2)
in 1997 and 1996, respectively and minority interest of $22.2 in 1996 -- 17.5 (109.4)
- --------------------------------------------------------------------------------------------------------------------
Earnings (loss) from discontinued operations -- 17.5 (164.2)
- --------------------------------------------------------------------------------------------------------------------
Earnings before extraordinary item 396.4 94.0 208.2
Extraordinary item, loss related to early retirement of
debt, net of income tax benefit of $11.4 -- (17.1) --
- --------------------------------------------------------------------------------------------------------------------
Net earnings 396.4 76.9 $ 208.2
Preference dividends, net of income tax benefit (13.6) (13.7) (14.5)
- --------------------------------------------------------------------------------------------------------------------
Net earnings available to common shareholders $ 382.8 $ 63.2 $ 193.7
====================================================================================================================
Basic earnings per common share:
Earnings from continuing operations before extraordinary item $ 0.99 $ 0.17 $ 0.98
Earnings (loss) from discontinued operations -- 0.05 (0.45)
Extraordinary item, net of tax benefit -- (0.05) --
- --------------------------------------------------------------------------------------------------------------------
Net earnings $ 0.99 $ 0.17 $ 0.53
- --------------------------------------------------------------------------------------------------------------------
Weighted average common shares outstanding 387.1 377.2 366.9
====================================================================================================================
Diluted earnings per common share:
Earnings from continuing operations before extraordinary item $ 0.98 $ 0.16 $ 0.95
Earnings (loss) from discontinued operations -- 0.05 (0.43)
Extraordinary item, net of tax benefit -- (0.05) --
- --------------------------------------------------------------------------------------------------------------------
Net earnings $ 0.98 $ 0.16 $ 0.52
====================================================================================================================
Weighted average common shares outstanding 405.2 385.1 383.6
====================================================================================================================
Dividends per common share $ 0.225 $ 0.220 $ 0.220
====================================================================================================================
</TABLE>
See accompanying notes to consolidated financial statements.
22
<PAGE>
Consolidated Balance Sheets
<TABLE>
<CAPTION>
=========================================================================================================================
December 31,
In millions, except per share amounts 1998 1997
- -------------------------------------------------------------------------------------------------------------------------
<S> <C> <C>
Assets:
Cash and cash equivalents $ 180.8 $ 192.5
Accounts receivable, net 650.3 452.4
Inventories 3,190.2 2,882.4
Other current assets 327.9 364.8
- -------------------------------------------------------------------------------------------------------------------------
Total current assets 4,349.2 3,892.1
Property and equipment, net 1,351.2 1,072.3
Goodwill, net 724.6 711.5
Deferred charges and other assets 311.2 303.0
- -------------------------------------------------------------------------------------------------------------------------
Total assets $6,736.2 $5,978.9
=========================================================================================================================
Liabilities:
Accounts payable $1,286.3 $1,233.7
Accrued expenses 1,111.3 1,168.6
Short-term borrowings 771.1 466.4
Current maturities of long-term debt 14.6 41.9
- -------------------------------------------------------------------------------------------------------------------------
Total current liabilities 3,183.3 2,910.6
Long-term debt 275.7 290.4
Other long-term liabilities 166.6 163.3
Commitments and contingencies (Note 14)
Shareholders' equity:
Preferred stock, $0.01 par value: authorized 120,619 shares; 0 shares issued and outstanding -- --
Preference stock, series one ESOP convertible, par value $1.00:
authorized 50,000,000 shares; issued and outstanding 5,239,000 shares at December 31, 1998
and 5,324,000 shares at December 31, 1997 280.0 284.6
Common stock, par value $0.01: authorized 1,000,000,000 shares; issued 401,380,000 shares at
December 31, 1998 and 393,734,000 shares at December 31, 1997 4.0 3.9
Treasury stock, at cost: 11,169,000 shares at December 31, 1998 and 11,278,0000 shares
at December 31, 1997 (260.2) (262.9)
Guaranteed ESOP obligation (270.7) (292.2)
Capital surplus 1,336.4 1,154.0
Retained earnings 2,021.1 1,727.2
- -------------------------------------------------------------------------------------------------------------------------
Total shareholders' equity 3,110.6 2,614.6
- -------------------------------------------------------------------------------------------------------------------------
Total liabilities and shareholders' equity $6,736.2 $5,978.9
=========================================================================================================================
</TABLE>
See accompanying notes to consolidated financial statements.
23
<PAGE>
Consolidated Statements of Shareholders' Equity
<TABLE>
<CAPTION>
========================================================================================================================
Years Ended December 31,
Shares Dollars
------------------------------ ------------------------------
In millions 1998 1997 1996 1998 1997 1996
- ------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Preference stock:
Beginning of year 5.3 5.6 6.3 $ 284.6 $ 298.6 $ 334.9
Conversion to common stock (0.1) (0.3) (0.7) (4.6) (14.0) (36.3)
- ------------------------------------------------------------------------------------------------------------------------
End of year 5.2 5.3 5.6 280.0 284.6 298.6
========================================================================================================================
Common stock:
Beginning of year 393.7 369.3 357.5 3.9 3.7 357.5
Stock options exercised and awards under stock plans 7.5 10.9 4.1 0.1 0.1 4.1
Effect of change in par value -- -- -- -- -- (365.6)
Other 0.2 13.5 7.7 -- 0.1 7.7
- ------------------------------------------------------------------------------------------------------------------------
End of year 401.4 393.7 369.3 4.0 3.9 3.7
========================================================================================================================
Treasury stock:
Beginning of year (11.3) (11.7) (13.1) (262.9) (273.1) (304.6)
Conversion of preference stock 0.2 0.5 1.4 4.2 12.2 31.6
Other (0.1) (0.1) -- (1.5) (2.0) (0.1)
- ------------------------------------------------------------------------------------------------------------------------
End of year (11.2) (11.3) (11.7) (260.2) (262.9) (273.1)
========================================================================================================================
Guaranteed ESOP obligation:
Beginning of year (292.2) (292.2) (309.7)
Reduction of guaranteed ESOP obligation 21.5 -- 17.5
- ------------------------------------------------------------------------------------------------------------------------
End of year (270.7) (292.2) (292.2)
========================================================================================================================
Capital surplus:
Beginning of year 1,154.0 941.2 532.4
Conversion of preference stock 0.3 1.8 4.7
Stock options exercised and awards under stock plans 176.2 195.9 56.7
Effect of change in par value -- -- 365.6
Other 5.9 15.1 (18.2)
- ------------------------------------------------------------------------------------------------------------------------
End of year 1,336.4 1,154.0 941.2
========================================================================================================================
Retained earnings:
Beginning of year 1,727.2 1,737.9 1,956.7
Net earnings 396.4 76.9 208.2
Dividends:
Preference stock, net of tax benefit (13.6) (13.7) (14.4)
Redeemable preferred stock -- -- (0.1)
Common stock (88.9) (73.9) (51.7)
Footstar distribution -- -- (360.8)
- ------------------------------------------------------------------------------------------------------------------------
End of year 2,021.1 1,727.2 1,737.9
========================================================================================================================
Other:
Beginning of year -- (2.4) 0.2
Cumulative translation adjustment -- -- (0.2)
Unrealized holding gain (loss) on investments, net -- 2.4 (2.4)
- ------------------------------------------------------------------------------------------------------------------------
End of year -- -- (2.4)
========================================================================================================================
Total shareholders' equity $3,110.6 $2,614.6 $2,413.7
========================================================================================================================
</TABLE>
See accompanying notes to consolidated financial statements.
24
<PAGE>
Consolidated Statements of Cash Flows
<TABLE>
<CAPTION>
===================================================================================================================================
Years Ended December 31,
In millions 1998 1997 1996
- -----------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Cash flows from operating activities:
Net earnings $ 396.4 $ 76.9 $ 208.2
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities:
Depreciation and amortization 249.7 242.6 262.8
Merger, restructuring and other non-recurring charges 168.3 486.7 235.0
Deferred income taxes and other non-cash items 81.8 (218.5) 116.4
Net operating loss carryforwards utilized 7.2 69.4 15.3
Gain on sale of securities -- -- (121.4)
Extraordinary item, loss on early retirement of debt, net of tax -- 17.1 --
Income (loss) from unconsolidated subsidiary -- 0.3 (4.5)
Minority interest in net earnings -- -- 22.2
Change in assets and liabilities, excluding acquisitions and dispositions:
(Increase) in accounts receivable, net (197.9) (82.5) (0.8)
(Increase) in inventories (315.0) (566.1) (251.0)
(Increase) in other current assets, deferred charges and other assets (82.7) (74.2) (99.1)
Increase in accounts payable 52.6 174.7 176.5
(Decrease) in accrued expenses (280.4) (220.3) (215.5)
Increase (decrease) in federal income taxes payable and other liabilities 141.0 (11.9) (16.9)
- -----------------------------------------------------------------------------------------------------------------------------------
Net cash provided by (used in) operating activities 221.0 (105.8) 327.2
===================================================================================================================================
Cash flows from investing activities:
Additions to property and equipment (502.3) (341.6) (328.9)
Acquisitions, net of cash (62.2) -- (373.9)
Proceeds from sale of businesses and other property and equipment 50.5 192.7 240.4
Proceeds from sale of investments -- 309.7 485.8
- -----------------------------------------------------------------------------------------------------------------------------------
Net cash (used in) provided by investing activities (514.0) 160.8 23.4
===================================================================================================================================
Cash flows from financing activities:
Additions to (reductions in) short-term borrowings 304.6 466.4 (52.0)
Proceeds from exercise of stock options 121.1 169.1 62.1
(Reductions in) additions to long-term debt (41.9) (917.2) 128.5
Dividends paid (102.5) (87.6) (137.5)
Other -- -- (25.8)
- -----------------------------------------------------------------------------------------------------------------------------------
Net cash provided by (used in) financing activities 281.3 (369.3) (24.7)
===================================================================================================================================
Net (decrease) increase in cash and cash equivalents (11.7) (314.3) 325.9
Cash and cash equivalents at beginning of year 192.5 506.8 180.9
- -----------------------------------------------------------------------------------------------------------------------------------
Cash and cash equivalents at end of year $ 180.8 $ 192.5 $ 506.8
===================================================================================================================================
</TABLE>
See accompanying notes to consolidated financial statements.
25
<PAGE>
Notes to Consolidated Financial Statements
1 Significant
Accounting Policies
Description of business ~ CVS Corporation ("CVS" or the "Company") is
principally in the retail drugstore business. As of December 31, 1998, the
Company operated 4,122 retail drugstores, located in 24 Northeast, Mid-Atlantic,
Southeast and Midwest states and the District of Columbia. See Note 12 for
further information about the Company's business segments.
Basis of presentation ~ The consolidated financial statements include the
accounts of the Company and its wholly-owned subsidiaries. All material
intercompany balances and transactions have been eliminated. As a result of the
Company's strategic restructuring program, the results of operations of the
former Footwear, Apparel, and Toys and Home Furnishings segments have been
classified as discontinued operations in the accompanying consolidated
statements of operations. See Note 4 for further information about the Company's
strategic restructuring program and discontinued operations.
Stock split ~ On May 13, 1998, the Company's shareholders approved an increase
in the number of authorized common shares from 300 million to one billion. Also
on that date, the Board of Directors authorized a two-for-one common stock
split, which was effected by the issuance of one additional share of common
stock for each share of common stock outstanding. These shares were distributed
on June 15, 1998 to shareholders of record as of May 25, 1998. All share and per
share amounts presented herein have been restated to reflect the effect of the
stock split.
Cash and cash equivalents ~ Cash and cash equivalents consist of cash and
temporary investments with maturities of three months or less when purchased.
Accounts receivable ~ Accounts receivable are stated net of an allowance for
uncollectible accounts of $39.8 million and $39.2 million as of December 31,
1998 and 1997, respectively. The balance primarily includes trade receivables
due from managed care organizations, pharmacy benefit management companies,
insurance companies, governmental agencies and vendors.
Inventories ~ Inventories are stated at the lower of cost or market using the
first-in, first-out method.
Financial instruments ~ The Company's financial instruments include cash and
cash equivalents, accounts receivable, accounts payable, accrued expenses and
short-term borrowings. Due to the short-term nature of these instruments, the
Company's carrying value approximates fair value. The Company also utilizes
letters of credit to guarantee certain foreign purchases. As of December 31,
1998 and 1997, approximately $62.4 million and $58.2 million, respectively, was
outstanding under letters of credit.
Property and equipment ~ Depreciation of property and equipment is computed on a
straight-line basis, generally over the estimated useful lives of the asset or,
when applicable, the term of the lease, whichever is shorter. Estimated useful
lives generally range from 10 to 40 years for buildings and improvements, 3 to
10 years for fixtures and equipment, and 3 to 10 years for leasehold
improvements. Maintenance and repair costs are charged directly to expense as
incurred. Major renewals or replacements that substantially extend the useful
life of an asset are capitalized and depreciated.
Impairment of long-lived assets ~ The Company primarily groups and evaluates
assets at an individual store level, which is the lowest level at which
individual cash flows can be identified. When evaluating assets for potential
impairment, the Company considers historical performance and estimated
undiscounted future cash flows. If the carrying amount of the related assets
exceed the expected future cash flows, the Company considers the assets to be
impaired and records an impairment loss.
Deferred charges and other assets ~ Deferred charges and other assets primarily
include beneficial leasehold costs, which are amortized on a straight-line basis
over the shorter of 15 years or the remaining life of the leasehold acquired,
and reorganization goodwill, which is amortized on a straight-line basis over 20
years. The reorganization goodwill is the value of Revco D.S., Inc., in excess
of identifiable assets, as determined during its 1992 reorganization under
Chapter 11 of the United States Bankruptcy Code. See Note 11 for further
information about reorganization goodwill.
Goodwill ~ Goodwill, which represents the excess of the purchase price over the
fair value of net assets acquired, is amortized on a straight-line basis
generally over periods of 40 years. Accumulated amortization was $85.6 million
and $65.6 million at December 31, 1998 and 1997, respectively. The Company
evaluates goodwill for impairment whenever events or circumstances indicate that
the carrying amount may not be recoverable. If the carrying amount of the
goodwill exceeds the expected undiscounted future cash flows, the Company
records an impairment loss.
Store opening and closing costs ~ New store opening costs are charged directly
to expense when incurred. When the
26
<PAGE>
Notes to Consolidated Financial Statements
Company closes a store, the estimated unrecoverable costs, including the
remaining lease obligation, are charged to expense in the year of the closing.
Advertising costs ~ External costs incurred to produce media advertising are
expensed when the advertising takes place.
Income taxes ~ Deferred tax assets and liabilities are recognized for the future
tax consequences attributable to differences between the carrying amount of
assets and liabilities for financial reporting purposes and the amounts used for
income tax purposes as well as for the deferred tax effects of tax credit
carryforwards. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those
temporary differences are expected to be recovered or settled.
Stock-based compensation ~ During 1996, the Company adopted Statement of
Financial Accounting Standards ("SFAS") No. 123, "Accounting for Stock-Based
Compensation." Under SFAS No. 123, companies can elect to account for
stock-based compensation using a fair value based method or continue to measure
compensation expense using the intrinsic value method prescribed in Accounting
Principles Board Opinion ("APB") No. 25, "Accounting for Stock Issued to
Employees." The Company has elected to continue to account for its stock-based
compensation plans under APB No. 25. See Note 7 for further information about
the Company's stock incentive plans.
Insurance ~ The Company is self-insured up to certain limits for general
liability, workers compensation and automobile liability claims. The Company
accrues for projected losses in the year the claim is incurred based on
actuarial assumptions followed in the insurance industry and the Company's past
experience.
Use of estimates ~ The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts in the consolidated financial
statements and accompanying notes. Actual results could differ from those
estimates.
Reclassifications ~ Certain reclassifications have been made to the consolidated
financial statements of prior years to conform to the current year presentation.
Earnings per common share ~ During the fourth quarter of 1997, the Company
adopted SFAS No. 128, "Earnings Per Share" and restated previously reported
earnings per common share. Basic earnings per common share is computed by
dividing: (i) net earnings, after deducting the after-tax dividends on the ESOP
Preference Stock, by (ii) the weighted average number of common shares
outstanding during the year (the "Basic Shares").
Diluted earnings per common share normally assumes that the ESOP Preference
Stock is converted into common stock and all dilutive stock options are
exercised. Diluted earnings per common share is computed by dividing: (i) net
earnings, after accounting for the difference between the current dividends on
the ESOP Preference Stock and the common stock and after making adjustments for
certain non-discretionary expenses that are based on net earnings such as
incentive bonuses and profit sharing by (ii) Basic Shares plus the additional
shares that would be issued assuming that all dilutive stock options are
exercised and the ESOP Preference Stock is converted into common stock. In 1997,
the assumed conversion of the ESOP Preference Stock would have increased diluted
earnings per common share and, therefore, was not considered.
New accounting pronouncements ~ During 1998, the Company adopted: (i) SFAS No.
130, "Reporting Comprehensive Income," which established standards for the
reporting and display of comprehensive income and its components, (ii) SFAS No.
131, "Disclosures about Segments of an Enterprise and Related Information,"
which requires companies to report financial information based on how management
internally organizes data to make operating decisions and assess performance and
(iii) SFAS No. 132, "Employers' Disclosures about Pensions and Other
Postretirement Benefits," which revises the disclosure requirements for pensions
and other postretirement benefit plans. Adoption of the above disclosure
standards did not affect the Company's financial results. Comprehensive income
does not differ from the consolidated net earnings presented in the accompanying
consolidated statements of operations.
27
<PAGE>
Notes to Consolidated Financial Statements
2 Business Combinations
Merger Transactions
On March 31, 1998, CVS completed a merger with Arbor Drugs, Inc. ("Arbor"),
pursuant to which 37.8 million shares of CVS common stock were exchanged for all
of the outstanding common stock of Arbor (the "CVS/Arbor Merger"). Each
outstanding share of Arbor common stock was exchanged for 0.6364 shares of CVS
common stock. In addition, outstanding Arbor stock options were converted at the
same exchange ratio into options to purchase 5.3 million shares of CVS common
stock.
On May 29, 1997, CVS completed a merger with Revco D.S., Inc. ("Revco"),
pursuant to which 120.6 million shares of CVS common stock were exchanged for
all of the outstanding common stock of Revco (the "CVS/Revco Merger"). Each
outstanding share of Revco common stock was exchanged for 1.7684 shares of CVS
common stock. In addition, outstanding Revco stock options were converted at the
same exchange ratio into options to purchase 6.6 million shares of CVS common
stock.
The CVS/Arbor Merger and CVS/Revco Merger (collectively, the "Mergers")
constituted tax-free reorganizations and have been accounted for as pooling of
interests under Accounting Principles Board Opinion No. 16, "Accounting for
Business Combinations." Accordingly, all prior period financial statements
presented have been restated to include the combined results of operations,
financial position and cash flows of Arbor and Revco as if they had always been
owned by CVS.
Prior to the Mergers, Arbor's fiscal year ended on July 31 and Revco's fiscal
year ended on the Saturday closest to May 31. These fiscal year-ends have been
restated to a December 31 year-end to conform to CVS' fiscal year-end. Arbor's
and Revco's cost of sales and inventories have been restated from the last-in,
first-out method to the first-in, first-out method to conform to CVS' accounting
method for inventories. The impact of the restatement was to increase earnings
from continuing operations by $0.5 million in 1998, $1.2 million in 1997 and
$15.5 million in 1996.
There were no material transactions between CVS, Arbor and Revco prior to the
Mergers. Certain reclassifications have been made to Arbor's and Revco's
historical stand-alone financial statements to conform to CVS' presentation.
Following are the results of operations for the separate companies prior to the
Mergers and the combined amounts presented in the consolidated financial
statements:
<TABLE>
<CAPTION>
================================================================
Three Months Ended Years Ended
March 28, March 29, December 31,
In millions 1998 1997 1997 1996
- ----------------------------------------------------------------
<S> <C> <C> <C> <C>
Net sales:
CVS $3,333.6 $ 1,515.0 $12,738.2 $ 5,528.1
Arbor 267.9 237.0 1,011.4 886.8
Revco -- 1,645.8 -- 5,416.7
- ----------------------------------------------------------------
$3,601.5 $ 3,397.8 $13,749.6 $11,831.6
================================================================
Earnings from continuing operations:
CVS $ 121.3 $ 58.5 $ 37.3 $ 239.6
Arbor 10.7 9.4 39.2 31.6
Revco -- 24.2 -- 101.2
- ----------------------------------------------------------------
$ 132.0 $ 92.1 $ 76.5 $ 372.4
================================================================
</TABLE>
Purchase Transactions
On December 23, 1996, the Company completed the cash purchase of Big B, Inc.
("Big B") by acquiring all of the outstanding shares of Big B common stock. The
aggregate transaction value, including the assumption of $49.3 million of Big B
debt, was $423.2 million. The Big B acquisition was accounted for as a purchase
business combination. The resulting excess of purchase price over net assets
acquired, $248.9 million, is being amortized on a straight-line basis over 40
years. For financial reporting purposes, Big B's results of operations have been
included in the consolidated financial statements since November 16, 1996.
The Company also acquired other retail drugstore businesses that were accounted
for as purchase business combinations. These acquisitions did not have a
material effect on the consolidated financial statements either individually or
in the aggregate. The results of operations of these companies have been
included in the consolidated financial statements since their respective dates
of acquisition.
28
<PAGE>
Notes to Consolidated Financial Statements
3 Merger & Restructuring Charges
In accordance with Emerging Issues Task Force ("EITF") Issue No. 94-3,
"Liability Recognition for Certain Employee Termination Benefits and Other Costs
to Exit an Activity (Including Certain Costs Incurred in a Restructuring)" and
SFAS No. 121, "Accounting for the Impairment of Long-Lived Assets and for
Long-Lived Assets to Be Disposed Of," the Company recorded the following charges
in connection with the Mergers.
In connection with the CVS/Arbor Merger, the Company recorded a $158.3 million
charge to operating expenses during the second quarter of 1998 for direct and
other merger-related costs pertaining to the merger transaction and certain
restructuring activities (the "CVS/Arbor Charge"). Asset write-offs included in
this charge totaled $41.2 million. The balance of the charge, $117.1 million,
will require cash outlays of which $60.1 million had been incurred as of
December 31, 1998. The remaining cash outlays primarily include noncancelable
lease commitments and severance. The Company also recorded a $10.0 million
charge to cost of goods sold during the second quarter of 1998 to reflect
markdowns on noncompatible Arbor merchandise (the "Arbor Inventory Markdown").
In connection with the CVS/Revco Merger, the Company recorded a $411.7 million
charge to operating expenses during the second quarter of 1997 for direct and
other merger-related costs pertaining to the merger transaction and certain
restructuring activities (the "CVS/Revco Charge"). Asset write-offs included in
this charge totaled $82.2 million. The balance of the charge, $329.5 million,
will require cash outlays of which $269.3 million had been incurred as of
December 31, 1998. The remaining cash outlays primarily include non-cancelable
lease commitments and severance. The Company also recorded a $75.0 million
charge to cost of goods sold during the second quarter of 1997 to reflect
markdowns on noncompatible Revco merchandise (the "Revco Inventory Markdown").
Merger transaction costs primarily include fees for investment bankers,
attorneys, accountants, financial printing and other related charges. Employee
severance and benefits primarily include costs associated with terminating
approximately 200 Arbor and 1,000 Revco employees, all of which had occurred as
of December 31, 1998. Noncancelable lease obligations and duplicate facilities
primarily include noncancelable lease commitments and shut down costs. These
costs did not provide future benefit to the retained stores or corporate
facilities.
In accordance with EITF 94-3 and SFAS No. 121, the Company also recorded a $31.0
million charge to operating expenses during the first quarter of 1997 for
certain costs associated with the restructuring of Big B (the "Big B Charge").
This charge included accrued liabilities related to certain exit plans for
identified stores and duplicate corporate facilities, such as the cancellation
of lease agreements and the write-down of unutilized fixed assets. Asset
write-offs included in this charge totaled $5.1 million. The balance of the
charge, $25.9 million, will require cash outlays of which $10.0 million had been
incurred as of December 31, 1998. The remaining cash outlays primarily include
noncancelable lease commitments. These exit plans did not provide future benefit
to the retained stores or corporate facilities.
Following is a summary of the significant components of the above charges:
<TABLE>
<CAPTION>
====================================================================================================================================
CVS/Arbor Charge CVS/Revco and Big B Charges
----------------------------------------------- -----------------------------------------------
Total 1998 Utilized Balance at Total 1997 Utilized Balance at
In millions Charge to Date Transfer 12/31/98(1) Charges to Date Transfer 12/31/98(1)
- ------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Merger transaction costs $ 15.0 $ (15.9) $ 0.9 $ -- $ 35.0 $ (32.4) $ (2.6) $ --
Restructuring costs:
Employee severance
and benefits 27.1 (13.8) 0.3 13.6 89.8 (77.4) -- 12.4
Exit costs:
Noncancelable lease
obligations and
duplicate facilities 67.5 (25.8) (1.9) 39.8 211.6 (147.9) -- 63.7
Fixed asset write-offs 41.2 (41.2) -- -- 87.3 (87.3) -- --
Contract cancellation costs 4.8 (1.2) -- 3.6 7.4 (7.4) -- --
Other 2.7 (3.4) 0.7 -- 11.6 (14.2) 2.6 --
- ------------------------------------------------------------------------------------------------------------------------------------
$ 158.3 $ (101.3) $ -- $ 57.0 $ 442.7 $ (366.6) $ -- $ 76.1
====================================================================================================================================
</TABLE>
(1) The Company believes that the reserve balances at December 31, 1998 are
adequate to cover the remaining liabilities associated with these charges.
29
<PAGE>
Notes to Consolidated Financial Statements
Strategic Restructuring Program &
4 Discontinued Operations
In November 1997, the Company completed the final phase of its comprehensive
strategic restructuring program, first announced in October 1995 and
subsequently refined in May 1996 and June 1997. The strategic restructuring
program included: (i) the sale of Marshalls, Kay-Bee Toys, Wilsons, This End Up
and Bob's Stores, (ii) the spin-off of Footstar, Inc., which included Meldisco,
Footaction and Thom McAn (the "Footstar Distribution"), (iii) the initial and
secondary public offerings of Linens `n Things and (iv) the elimination of
certain corporate overhead costs.
The strategic restructuring program was completed without significant changes to
the Board approved plan. As part of completing this program, the Company
recorded, as a component of discontinued operations, an after-tax charge of
$20.7 million during the second quarter of 1997 and $148.1 million during the
second quarter of 1996 to finalize original liability estimates. The Company
believes that the remaining pre-tax reserve balance of $84.7 million at December
31, 1998 is adequate to cover the remaining liabilities associated with this
program.
Following is a summary of the strategic restructuring reserve:
<TABLE>
<CAPTION>
================================================================
Total Utilized
In millions Reserve to Date Transfer Balance
- ----------------------------------------------------------------
<S> <C> <C> <C> <C>
Loss on disposal $ 721.8 $ (710.6) $38.8 $50.0
Lease obligations 187.4 (124.6) (32.8) 30.0
Severance 58.6 (47.9) (6.0) 4.7
Other 174.2 (174.2) -- --
- ----------------------------------------------------------------
$1,142.0 $(1,057.3) $ -- $84.7
================================================================
</TABLE>
Following is a summary of discontinued operations by reporting segment for the
years ended December 31:
<TABLE>
<CAPTION>
===============================================================
In millions 1997 1996
- ---------------------------------------------------------------
<S> <C> <C>
Net sales:
Footwear $ -- $1,391.1
Apparel 348.3 526.4
Toys and Home Furnishings -- 900.3
- ---------------------------------------------------------------
$348.3 $2,817.8
===============================================================
Operating (loss):
Footwear $ -- $ (12.4)
Apparel -- (171.3)
Toys and Home Furnishings -- (49.7)
- ---------------------------------------------------------------
$ -- $ (233.4)
===============================================================
</TABLE>
As of December 31, 1998 and 1997, there were no assets or liabilities of the
discontinued operations reflected in the accompanying consolidated balance
sheets.
5 Borrowings and Credit Agreements
Following is a summary of the Company's borrowings at December 31:
<TABLE>
<CAPTION>
==============================================================
In millions 1998 1997
- --------------------------------------------------------------
<S> <C> <C>
Commercial paper $736.6 $450.0
ESOP note payable(1) 270.7 292.1
Uncommitted lines of credit 34.5 16.4
9.125% senior notes -- 19.2
Mortgage notes payable 16.1 17.1
Capital lease obligations and other 3.5 3.9
- --------------------------------------------------------------
1,061.4 798.7
Less:
Short-term borrowings (771.1) (466.4)
Current portion of long-term debt (14.6) (41.9)
- --------------------------------------------------------------
$ 275.7 $ 290.4
==============================================================
</TABLE>
(1) See Note 9 for further information about the Company's ESOP Plan.
The Company's commercial paper program is supported by a $670 million, five-year
unsecured revolving credit facility, which expires on May 30, 2002 and a $460
million, 364 day unsecured revolving credit facility, which expires on June 26,
1999 (collectively, the "Credit Facilities"). The Credit Facilities require the
Company to pay a quarterly facility fee of 0.07%, regardless of usage. The
Company can also obtain up to $35.0 million of short-term financing through
various uncommitted lines of credit. The weighted average interest rate for
short-term borrowings was 5.7% as of December 31, 1998 and 1997.
The Company was not obligated under any formal or informal compensating balance
agreements.
During the second quarter of 1997, the Company extinguished $865.7 million of
the debt it absorbed as part of the CVS/Revco Merger using cash on hand and
commercial paper borrowings. As a result, the Company recorded an extraordinary
loss, net of income taxes, of $17.1 million, which consisted of early retirement
premiums and the write-off of unamortized deferred financing costs. On January
15, 1998, the Company redeemed the remaining $19.2 million of 9.125% senior
notes.
At December 31, 1998, the aggregate long-term debt maturing during the next five
years is as follows: $14.6 million in 1999, $17.3 million in 2000, $21.6 million
in 2001, $26.5 million in 2002, $32.3 million in 2003, $178.0 million in 2004
and thereafter. Interest paid was approximately $70.7 million in 1998, $58.4
million in 1997 and $79.8 million in 1996.
30
<PAGE>
Notes to Consolidated Financial Statements
6 Leases
The Company and its subsidiaries lease retail stores, warehouse facilities and
office facilities under noncancelable operating leases over periods ranging from
5 to 20 years, and generally have options to renew such terms over periods
ranging from 5 to 15 years.
Following is a summary of the Company's net rental expense for operating leases
for the years ended December 31:
<TABLE>
<CAPTION>
===============================================================
In millions 1998 1997 1996
- ---------------------------------------------------------------
<S> <C> <C> <C>
Minimum rentals $ 459.1 $ 409.6 $ 337.4
Contingent rentals 60.3 60.2 73.6
- ---------------------------------------------------------------
519.4 469.8 411.0
Less: sublease income (14.0) (9.5) (12.8)
- ---------------------------------------------------------------
$ 505.4 $ 460.3 $ 398.2
===============================================================
</TABLE>
Following is a summary of the future minimum lease payments under capital and
operating leases, excluding lease obligations for closed stores, at December 31,
1998:
<TABLE>
<CAPTION>
===============================================================
Capital Operating
In millions Leases Leases
- ---------------------------------------------------------------
<S> <C> <C>
1999 $ 0.4 $ 402.6
2000 0.4 381.1
2001 0.4 348.3
2002 0.2 323.3
2003 0.2 297.7
Thereafter 1.3 2,485.7
- ---------------------------------------------------------------
2.9 $ 4,238.7
Less: imputed interest (1.4)
- ---------------------------------------------------------------
Present value of capital lease obligations $ 1.5
===============================================================
</TABLE>
7 Stock Incentive Plans
As of December 31, 1998, the Company had the following stock incentive plans
(including the pre-merger plans of Arbor and Revco). Effective with the Mergers,
outstanding Arbor and Revco stock options were exchanged for options to purchase
CVS common stock.
1997 Incentive Compensation Plan
The 1997 Incentive Compensation Plan (the "1997 ICP"), superseded the 1990
Omnibus Stock Incentive Plan, the 1987 Stock Option Plan and the 1973 Stock
Option Plan (collectively, the "Preexisting Plans"). Upon approval of the 1997
ICP, authority to make future grants under the Preexisting Plans was terminated,
although previously granted awards remain outstanding in accordance with their
terms and the terms of the Preexisting Plans.
As of December 31, 1998, the 1997 ICP provided for the granting of up to
23,321,821 shares of common stock in the form of stock options, stock
appreciation rights ("SARs"), restricted shares, deferred shares and
performance-based awards to selected officers, employees and directors of the
Company. All grants under the 1997 ICP are awarded at fair market value on the
date of grant. The right to exercise or receive these awards generally commences
between one and five years from the date of the grant and expires not more than
ten years after the date of the grant, provided that the holder continues to be
employed by the Company. As of December 31, 1998, there were 19,730,690 shares
available for grant under the 1997 ICP.
Restricted shares issued under the 1997 ICP may not exceed 3.6 million shares.
In 1998, 1997 and 1996, 155,400, 44,610 and 633,100 shares of restricted stock
were granted at a weighted average grant date fair value of $37.80, $23.02 and
$13.14, respectively. Participants are entitled to vote and receive dividends on
their restricted shares, although they are subject to certain transfer
restrictions. Performance-based awards, which are subject to the achievement of
certain business performance goals, totaled 56,346 at a weighted average grant
date fair value of $36.70 in 1998. No awards were granted in 1997 and 1996.
Compensation cost, which is based on the fair value at the date of grant, is
recognized over the restricted or performance period. This cost totaled $3.1
million in 1998, $3.5 million in 1997 and $3.9 million in 1996.
The 1996 Directors Stock Plan
The 1996 Directors Stock Plan (the "1996 DSP"), provides for the granting of up
to 346,460 shares of common stock to the Company's non-employee directors (the
"Eligible Directors"). The 1996 DSP allows the Eligible Directors to elect to
receive shares of common stock in lieu of cash compensation. Eligible Directors
may also elect to defer compensation payable in common stock until their service
as a director concludes. The 1996 DSP replaced the Company's 1989 Directors
Stock Option Plan. As of December 31, 1998, there were 263,554 shares available
for grant under the 1996 DSP.
31
<PAGE>
Notes to Consolidated Financial Statements
Following is a summary of the fixed stock option activity under the 1997 ICP,
the Preexisting Plans and the pre-merger plans of Arbor and Revco for the years
ended December 31:
<TABLE>
<CAPTION>
===================================================================================================================================
1998 1997 1996
-------------------------------- -------------------------------- --------------------------------
Weighted Average Weighted Average Weighted Average
Shares Exercise Price Shares Exercise Price Shares Exercise Price
- -----------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Outstanding at beginning of year 16,070,146 $ 16.95 23,569,930 $ 13.96 25,782,040 $ 14.06
Granted 3,119,410 37.16 3,695,530 23.62 6,609,229 14.80
Exercised (7,137,027) 15.01 (10,756,726) 12.99 (3,534,729) 11.62
Canceled (70,407) 26.48 (438,588) 14.48 (5,286,610) 17.35
- -----------------------------------------------------------------------------------------------------------------------------------
Outstanding at end of year 11,982,122 23.31 16,070,146 16.95 23,569,930 13.96
- -----------------------------------------------------------------------------------------------------------------------------------
Exercisable at end of year 6,127,402 11,729,688 10,011,179
===================================================================================================================================
</TABLE>
Following is a summary of the fixed stock options outstanding and exercisable as
of December 31, 1998:
<TABLE>
<CAPTION>
===================================================================================================================================
Options Outstanding Options Exercisable
------------------------------------------------------------ ----------------------------------------
Range of Number Weighted Average Weighted Average Number Weighted Average
Exercise Prices Outstanding Remaining Life Exercise Price Exercisable Exercise Price
- -----------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
$ 5.00 to $20.00 6,024,451 5.5 $16.29 5,358,465 $16.24
20.01 to 35.00 2,857,611 7.1 23.10 697,787 22.20
35.01 to 46.50 3,100,060 9.1 37.16 71,150 37.45
- -----------------------------------------------------------------------------------------------------------------------------------
$ 5.00 to $46.50 11,982,122 6.8 $23.31 6,127,402 $17.16
===================================================================================================================================
</TABLE>
The Company applies APB Opinion No. 25 to account for its stock incentive plans.
Accordingly, no compensation cost has been recognized for stock options granted.
Had compensation cost been recognized based on the fair value of stock options
granted consistent with SFAS No. 123, net earnings and net earnings per common
share ("EPS") would approximate the pro forma amounts shown below for the years
ended December 31.
<TABLE>
<CAPTION>
=====================================================================
In millions, except per share amounts 1998 1997 1996
- ---------------------------------------------------------------------
<S> <C> <C> <C>
Net earnings:
As reported $396.4 $76.9 $208.2
Pro forma 370.9 58.7 196.2
- ---------------------------------------------------------------------
Basic EPS:
As reported $ 0.99 $0.17 $ 0.53
Pro forma 0.92 0.12 0.50
- ---------------------------------------------------------------------
Diluted EPS:
As reported $ 0.98 $0.16 $ 0.52
Pro forma 0.91 0.12 0.49
=====================================================================
</TABLE>
Beginning with grants made on or after January 1, 1995, the fair value of each
stock option grant was estimated using the Black-Scholes Option Pricing Model
with the following assumptions:
=============================================================
1998 1997 1996
- -------------------------------------------------------------
Dividend yield 0.40% 0.70% 1.07%
Expected volatility 22.49% 22.77% 20.51%
Risk-free interest rate 5.75% 5.50% 7.00%
Expected life 7.0 5.5 5.0
=============================================================
Pension Plans and
8 Other Postretirement Benefits
The Company sponsors various retirement programs, including defined benefit,
defined contribution and other plans that cover most full-time employees.
Defined Benefit Plans
The Company sponsors a non-contributory defined benefit pension plan that covers
certain full-time employees of Revco who are not covered by collective
bargaining agreements. On September 20, 1997, the Company suspended future
benefit accruals under this plan. As a result of the plan's suspension, the
Company realized a $6.0 million curtailment gain in 1997. Benefits paid to
retirees are based upon age at retirement, years of credited service and average
compensation during the five year period ending September 20, 1997. It is the
Company's policy to fund this plan based on actuarial calculations and
applicable federal regulations.
Pursuant to various labor agreements, the Company is required to make
contributions to certain union-administered pension plans that totaled $1.5
million in 1998, $1.6 million in 1997 and $1.2 million in 1996. The Company may
be liable for its share of the plans' unfunded liabilities if the plans are
terminated. The Company also has non-qualified supplemental executive retirement
plans ("SERPs") in place for certain key employees for whom it has purchased
cost recovery variable life insurance.
32
<PAGE>
Notes to Consolidated Financial Statements
Defined Contribution Plans
The Company sponsors a Profit Sharing Plan and a 401(k) Savings Plan that cover
substantially all employees who meet plan eligibility requirements. The Company
also maintains a non-qualified, unfunded Deferred Compensation Plan for certain
key employees. The Company's contributions under the above defined contribution
plans totaled $26.4 million in 1998, $24.1 million in 1997 and $19.5 million in
1996. The Company also sponsors an Employee Stock Ownership Plan. See Note 9 for
further information about this plan.
Other Postretirement Benefits
The Company provides postretirement health care and life insurance benefits to
retirees who meet eligibility requirements. The Company's funding policy is
generally to pay covered expenses as they are incurred.
Following is a reconciliation of the benefit obligation, fair value of plan
assets and funded status of the Company's defined benefit and other
postretirement benefit plans:
<TABLE>
<CAPTION>
===================================================================================================================================
Defined Benefit Plans Other Postretirement Benefits
In millions 1998 1997 1998 1997
- -----------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Change in benefit obligation:
Benefit obligation at beginning of year $ 253.3 $ 255.1 $ 14.4 $ 15.5
Service cost 0.5 7.6 -- --
Interest cost 19.5 19.2 1.0 1.0
Actuarial loss (gain) 49.3 (10.4) 0.5 (0.7)
Benefits paid (25.0) (18.2) (1.9) (1.4)
- -----------------------------------------------------------------------------------------------------------------------------------
Benefit obligation at end of year $ 297.6 $ 253.3 $ 14.0 $ 14.4
===================================================================================================================================
Change in plan assets:
Fair value at beginning of year $ 201.5 $ 172.8 $ -- $ --
Actual return on plan assets 28.4 20.0 -- --
Company contributions 18.2 26.9 1.9 1.4
Benefits paid (25.0) (18.2) (1.9) (1.4)
- -----------------------------------------------------------------------------------------------------------------------------------
Fair value at end of year(1) $ 223.1 $ 201.5 $ -- $ --
===================================================================================================================================
Funded status:
Funded status $ (74.5) $ (51.8) $ (14.0) $ (14.5)
Unrecognized prior service cost 1.3 1.6 (1.0) (1.1)
Unrecognized net loss (gain) 1.6 (8.4) (0.3) (1.0)
- -----------------------------------------------------------------------------------------------------------------------------------
Accrued pension costs $ (71.6) $ (58.6) $ (15.3) $ (16.6)
===================================================================================================================================
Weighted average assumptions:
Discount rate 6.75% 7.25% 6.75% 7.25%
Expected return on plan assets 9.00% 9.00% -- --
Rate of compensation increase 4.50% 4.50% -- --
===================================================================================================================================
</TABLE>
(1) Plan assets consist primarily of mutual funds, common stock and insurance
contracts.
For measurement purposes, future health care costs are assumed to increase at an
annual rate of 6.5% during 1999, decreasing to an annual growth rate of 5.0% in
2002 and thereafter. A one percent change in the assumed health care cost trend
rate would change the accumulated postretirement benefit obligation by $1.0
million and the total service and interest costs by $0.1 million.
Following is a summary of the net periodic pension cost for the defined benefit
and other postretirement benefit plans:
<TABLE>
<CAPTION>
===================================================================================================================================
Defined Benefit Plans Other Postretirement Benefits
In millions 1998 1997 1996 1998 1997 1996
- -----------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Service cost(1) $ 0.5 $ 7.6 $ 9.2 $ -- $ -- $ 0.4
Interest cost on benefit obligation 19.5 19.2 16.8 1.0 1.0 2.5
Expected return on plan assets (16.4) (14.9) (18.2) -- -- --
Amortization of net loss (gain) 1.2 0.3 6.1 (0.2) -- (1.1)
Amortization of prior service cost 0.1 0.3 0.4 (0.1) (0.3) --
Curtailment gain -- (6.0) (1.3) -- -- --
- -----------------------------------------------------------------------------------------------------------------------------------
Net periodic pension cost $ 4.9 $ 6.5 $ 13.0 $ 0.7 $ 0.7 $ 1.8
===================================================================================================================================
</TABLE>
(1) The decrease in total service cost is primarily due to the suspension of
future benefit accruals under the Revco pension plan during 1997.
33
<PAGE>
Notes to Consolidated Financial Statements
9 Employee Stock Ownership Plan
The Company sponsors a defined contribution Employee Stock Ownership Plan (the
"ESOP") that covers full-time employees with at least one year of service.
In 1989, the ESOP Trust borrowed $357.5 million through a 20-year note (the
"ESOP Note"). The proceeds from the ESOP Note were used to purchase 6.7 million
shares of Series One ESOP Convertible Preference Stock (the "ESOP Preference
Stock") from the Company. Since the ESOP Note is guaranteed by the Company, the
outstanding balance is reflected as long-term debt and a corresponding
Guaranteed ESOP obligation is reflected in shareholders' equity in the
accompanying consolidated balance sheets.
Each share of ESOP Preference Stock has a guaranteed minimum liquidation value
of $53.45, is convertible into 2.314 shares of common stock and is entitled to
receive an annual dividend of $3.90 per share. The ESOP Trust uses the dividends
received and contributions from the Company to repay the ESOP Note. As the ESOP
Note is repaid, ESOP Preference Stock is allocated to participants based on: (i)
the ratio of each year's debt service payment to total current and future debt
service payments multiplied by (ii) the number of unallocated shares of ESOP
Preference Stock in the plan. As of December 31, 1998, 5.2 million shares of
ESOP Preference Stock were outstanding, of which 1.6 million shares were
allocated to participants and the remaining 3.6 million shares were held in the
ESOP Trust for future allocations.
Annual ESOP expense recognized is equal to (i) the interest incurred on the ESOP
Note plus (ii) the higher of (a) the principal repayments or (b) the cost of the
shares allocated, less (iii) the dividends paid. Similarly, the Guaranteed ESOP
obligation is reduced by the higher of (i) the principal payments or (ii) the
cost of shares allocated.
Following is a summary of the ESOP for the years ended December 31:
================================================================
In millions 1998 1997 1996
- ----------------------------------------------------------------
ESOP expense recognized $25.8 $13.8 $15.4
Dividends paid 20.5 20.8 21.8
Cash contributions 25.8 22.9 19.3
Interest costs incurred on ESOP loan 24.9 26.4 27.5
ESOP shares allocated 0.4 0.4 0.4
================================================================
10 Supplemental Information
Following are the components of amounts included in the consolidated balance
sheets as of December 31:
<TABLE>
<CAPTION>
===============================================================
In millions 1998 1997
- ---------------------------------------------------------------
<S> <C> <C>
Other current assets:
Deferred income taxes $ 248.7 $ 304.2
Supplies 16.8 13.6
Other 62.4 47.0
- ---------------------------------------------------------------
$ 327.9 $ 364.8
===============================================================
Property and equipment:
Land $ 91.0 $ 78.7
Buildings and improvements 290.2 231.5
Fixtures and equipment 1,178.4 938.9
Leasehold improvements 477.4 443.7
Capital leases 2.8 3.3
- ---------------------------------------------------------------
2,039.8 1,696.1
Accumulated depreciation and
amortization (688.6) (623.8)
- ---------------------------------------------------------------
$1,351.2 $1,072.3
===============================================================
Accrued expenses:
Taxes other than federal
income taxes $ 130.8 $ 127.5
Salaries and wages 99.4 99.6
Rent 92.2 84.8
Strategic restructuring reserve 84.7 102.8
Employee benefits 82.7 84.3
CVS/Revco/ Big B reserve 76.1 233.0
CVS/Arbor reserve 57.0 --
Other 488.4 436.6
- ---------------------------------------------------------------
$1,111.3 $1,168.6
===============================================================
</TABLE>
Following is a summary of the Company's non-cash financing activities for the
years ended December 31:
<TABLE>
<CAPTION>
===========================================================
In millions 1998 1997 1996
- -----------------------------------------------------------
<S> <C> <C> <C>
Fair value of assets acquired $62.2 $ -- $423.2
Cash paid 62.2 -- 373.9
- -----------------------------------------------------------
Liabilities assumed $ -- $ -- $ 49.3
- -----------------------------------------------------------
Equity securities or notes
received from sale of
businesses $ -- $52.0 $172.4
===========================================================
</TABLE>
Interest expense was $69.7 million in 1998, $59.1 million in 1997 and $84.7
million in 1996. Interest income was $8.8 million in 1998, $15.0 million in 1997
and $9.2 million in 1996.
34
<PAGE>
Notes to Consolidated Financial Statements
11 Income Taxes
Deferred income taxes reflect the net tax effects of the temporary differences
between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes.
The Company's income tax (provision) benefit for continuing operations for the
years ended December 31 consisted of the following:
<TABLE>
<CAPTION>
========================================================
In millions Federal State Total
- --------------------------------------------------------
<S> <C> <C> <C>
1998:
Current $(197.3) $(41.4) $(238.7)
Deferred (51.2) (25.0) (76.2)
- --------------------------------------------------------
$(248.5) $(66.4) $(314.9)
========================================================
1997:
Current $(182.5) $(68.5) $(251.0)
Deferred 82.1 28.1 110.2
- --------------------------------------------------------
$(100.4) $(40.4) $(140.8)
========================================================
1996:
Current $(195.6) $(54.9) $(250.5)
Deferred (17.7) (2.8) (20.5)
- --------------------------------------------------------
$(213.3) $(57.7) $(271.0)
========================================================
</TABLE>
Following is a reconciliation of the statutory income tax rate to the Company's
effective tax rate for the years ended December 31:
<TABLE>
<CAPTION>
================================================================
1998 1997 1996
- ----------------------------------------------------------------
<S> <C> <C> <C>
Statutory income tax rate 35.0% 35.0% 35.0%
State income taxes, net of
federal tax benefit 5.8 6.6 5.5
Goodwill and other 1.2 1.4 1.6
- ----------------------------------------------------------------
Effective tax rate before
merger related costs 42.0 43.0 42.1
Merger related costs (1) 2.3 21.8 --
- ----------------------------------------------------------------
Effective tax rate 44.3% 64.8% 42.1%
================================================================
</TABLE>
(1) Includes state tax effect.
Income taxes paid (refunded) were $102.6 million, $258.9 million and $(33.8)
million during the years ended December 31, 1998, 1997 and 1996, respectively.
Following is a summary of the significant components of the Company's deferred
tax assets and liabilities as of December 31:
<TABLE>
<CAPTION>
==========================================================
In millions 1998 1997
- ----------------------------------------------------------
<S> <C> <C>
Deferred tax assets:
Employee benefits $ 84.5 $119.0
Other assets 185.5 253.8
- ----------------------------------------------------------
Total deferred tax assets $270.0 $372.8
- ----------------------------------------------------------
Deferred tax liabilities:
Property and equipment $(44.0) $(27.0)
Inventories (1.6) (29.9)
Other liabilities -- (10.7)
- ----------------------------------------------------------
Total deferred tax liabilities (45.6) (67.6)
- ----------------------------------------------------------
Net deferred tax assets $224.4 $305.2
==========================================================
</TABLE>
Based on historical pre-tax earnings, the Company believes it is more likely
than not that the deferred tax assets will be realized.
As of December 31, 1998, the Company had federal net operating loss
carryforwards ("NOLs") of $3.7 million that are attributable to Revco for
periods prior to its emergence from Chapter 11. The benefits realized from these
NOLs should reduce reorganization goodwill. Accordingly, the tax benefit of such
NOLs utilized during the three years ended December 31, 1998, $7.2 million,
$69.4 million and $15.3 million for 1998, 1997 and 1996, respectively, has not
been included in the computation of the Company's income tax provision, but
instead has been reflected as reductions of reorganization goodwill.
On October 12, 1996, the Company completed the Footstar Distribution which is
believed to be tax-free to the Company and its shareholders based on a legal
opinion provided by outside counsel. However, since opinions of counsel are not
binding on the Internal Revenue Service or the courts, it could ultimately be
determined that the Footstar Distribution does not qualify as a tax-free
distribution. If such occurred, the Company would be required to recognize a
capital gain for tax purposes equal to the difference between the fair market
value of the shares of Footstar stock distributed and the Company's basis in
such shares. The Company, however, believes the likelihood of the Footstar
Distribution not qualifying as a tax-free distribution to be remote.
35
<PAGE>
Notes to Consolidated Financial Statements
12 Business Segments
The Company currently operates a Retail segment and a Pharmacy Benefit
Management ("PBM") segment. The Company's business segments are operating units
that offer different products and services, and require distinct technology and
marketing strategies.
The Retail segment, which is described in Note 1, is the Company's only
reportable segment.
The PBM segment provides a full range of prescription benefit management
services to managed care and other organizations. These services include plan
design and administration, formulary management, mail order pharmacy services,
claims processing and generic substitution.
The accounting policies of the segments are substantially the same as those
described in Note 1. The Company evaluates segment performance based on
operating profit, before the effect of non-recurring charges and gains and
intersegment profits.
Following is a reconciliation of the significant components of the Company's
consolidated net sales for the years ended December 31:
<TABLE>
<CAPTION>
==================================================
1998 1997 1996
- --------------------------------------------------
<S> <C> <C> <C>
Pharmacy(1) 57.6% 54.7% 51.6%
Front store 42.4 45.3 48.4
- --------------------------------------------------
Consolidated net sales 100.0% 100.0% 100.0%
==================================================
</TABLE>
(1) Pharmacy sales includes the Retail segment's pharmacy sales, the PBM
segment's total sales and the effect of the intersegment sales elimination
discussed in the table below.
Following is a reconciliation of the Company's business segments to the
consolidated financial statements:
<TABLE>
<CAPTION>
===========================================================================================================================
Retail PBM Intersegment Other Consolidated
In millions Segment Segment Eliminations(1) Adjustments(2) Totals
- ---------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
1998:
Net sales $15,081.1 $488.4 $(295.9) $ -- $15,273.6
Operating profit 927.8 12.7 -- (168.3) 772.2
Depreciation and amortization 248.6 1.1 -- -- 249.7
Total assets 6,652.1 119.6 (35.5) -- 6,736.2
Capital expenditures 498.0 4.3 -- -- 502.3
===========================================================================================================================
1997:
Net sales $13,649.4 $320.7 $(220.5) $ -- $13,749.6
Operating profit 771.2 7.9 -- (517.7) 261.4
Depreciation and amortization 237.8 0.4 -- -- 238.2
Total assets 5,937.3 60.6 (19.0) -- 5,978.9
Capital expenditures 339.6 2.0 -- -- 341.6
===========================================================================================================================
1996:
Net sales $11,766.3 $208.9 $(143.6) $ -- $11,831.6
Operating profit 602.5 2.2 -- (12.8) 591.9
Depreciation and amortization 205.2 0.2 -- -- 205.4
Total assets 6,003.5 32.8 (21.4) -- 6,014.9
Capital expenditures 326.9 2.0 -- -- 328.9
===========================================================================================================================
</TABLE>
(1) Intersegment eliminations relate to intersegment sales and accounts
receivables that occur when a PBM segment customer uses a Retail segment
store to purchase covered merchandise. When this occurs, both segments
record the sale on a stand-alone basis.
(2) Other adjustments relate to the merger and restructuring charges discussed
in Note 3 and a $12.8 million charge that was recorded when Rite Aid
Corporation withdrew its tender offer to acquire Revco. This event took
place in 1996 before the CVS/Revco Merger. The merger and restructuring
charges are not considered when management assesses the stand-alone
performance of the Company's business segments.
36
<PAGE>
Notes to Consolidated Financial Statements
13 Reconciliation of Earnings Per Common Share
Following is a reconciliation of basic and diluted earnings per common share for
the years ended December 31:
<TABLE>
<CAPTION>
=============================================================================================================
In millions, except per share amounts 1998 1997 1996
- -------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Numerator for earnings per common share calculation:
Earnings from continuing operations before extraordinary item $396.4 $ 76.5 $ 372.4
Preference dividends, net of tax benefit (13.6) (13.7) (14.5)
- -------------------------------------------------------------------------------------------------------------
Earnings from continuing operations available to common
shareholders, basic $382.8 $ 62.8 $ 357.9
- -------------------------------------------------------------------------------------------------------------
Earnings (loss) from discontinued operations -- 17.5 (164.2)
Extraordinary loss -- (17.1) --
- -------------------------------------------------------------------------------------------------------------
Net earnings available to common shareholders, basic $382.8 $ 63.2 $ 193.7
=============================================================================================================
Earnings from continuing operations before extraordinary item $396.4 $ 76.5 $ 372.4
Effect of dilutive securities:
Preference dividends, net of tax benefit -- (13.7) --
Dilutive earnings adjustments (0.8) -- (7.5)
- -------------------------------------------------------------------------------------------------------------
Earnings from continuing operations available to common
shareholders, diluted $395.6 $ 62.8 $ 364.9
- -------------------------------------------------------------------------------------------------------------
Earnings (loss) from discontinued operations -- 17.5 (164.2)
Extraordinary loss -- (17.1) --
- -------------------------------------------------------------------------------------------------------------
Net earnings available to common shareholders, diluted $395.6 $ 63.2 $ 200.7
=============================================================================================================
Denominator for earnings per common share calculation:
Weighted average common shares, basic 387.1 377.2 366.9
Effect of dilutive securities:
Preference stock 10.5 -- 11.7
Stock options 7.6 7.9 5.0
- -------------------------------------------------------------------------------------------------------------
Weighted average common shares, diluted 405.2 385.1 383.6
=============================================================================================================
Basic earnings per common share:
Earnings from continuing operations before extraordinary item $ 0.99 $ 0.17 $ 0.98
Earnings (loss) from discontinued operations -- 0.05 (0.45)
Extraordinary item, net of tax benefit -- (0.05) --
- -------------------------------------------------------------------------------------------------------------
Net earnings $ 0.99 $ 0.17 $ 0.53
=============================================================================================================
Diluted earnings per common share:
Earnings from continuing operations before extraordinary item $ 0.98 $ 0.16 $ 0.95
Earnings (loss) from discontinued operations -- 0.05 (0.43)
Extraordinary item, net of tax benefit -- (0.05) --
- -------------------------------------------------------------------------------------------------------------
Net earnings $ 0.98 $ 0.16 $ 0.52
=============================================================================================================
</TABLE>
37
<PAGE>
Notes to Consolidated Financial Statements
14 Commitments & Contingencies
In connection with certain business dispositions completed between 1991 and
1997, the Company continues to guarantee lease obligations for approximately
1,600 former stores. The Company is indemnified for these obligations by the
respective purchasers. Assuming that each respective purchaser became insolvent,
an event which the Company believes to be highly unlikely, management estimates
that it could settle these obligations for approximately $1.1 billion as of
December 31,1998. In the opinion of management, the ultimate disposition of
these guarantees will not have a material adverse effect on the Company's
consolidated financial condition, results of operations or future cash flows.
The Company is also a defendant in various lawsuits arising in the ordinary
course of business. In the opinion of management and the Company's outside
counsel, the ultimate disposition of these lawsuits, exclusive of potential
insurance recoveries, will not have a material adverse effect on the Company's
consolidated financial condition, results of operations or future cash flows.
15 Quarterly Financial Information (Unaudited)
<TABLE>
<CAPTION>
===================================================================================================================================
In millions, except per share amounts 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter
- -----------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Net sales:
1998 $ 3,601.5 $ 3,755.9 $ 3,725.1 $ 4,191.1
1997 3,397.8 3,406.8 3,328.7 3,616.3
- -----------------------------------------------------------------------------------------------------------------------------------
Gross margin:
1998 $ 1,006.9 $ 1,020.5 $ 995.3 $ 1,106.5
1997 967.9 873.0 905.6 971.8
- -----------------------------------------------------------------------------------------------------------------------------------
Earnings (loss) from continuing operations before extraordinary item:
1998 $ 132.0 $ 16.2 $ 102.4 $ 145.8
1997 92.1 (221.4) 82.2 123.6
- -----------------------------------------------------------------------------------------------------------------------------------
Net earnings (loss):
1998 $ 132.0 $ 16.2 $ 102.4 $ 145.8
1997 92.2 (221.1) 82.2 123.6
- -----------------------------------------------------------------------------------------------------------------------------------
Earnings (loss) per common share from continuing operations before
extraordinary item:
1998: Basic $ 0.34 $ 0.03 $ 0.25 $ 0.37
Diluted 0.33 0.03 0.25 0.36
1997: Basic 0.24 (0.60) 0.21 0.31
Diluted 0.23 (0.60) 0.20 0.31
- -----------------------------------------------------------------------------------------------------------------------------------
Net earnings (loss) per common share:
1998: Basic $ 0.34 $ 0.03 $ 0.25 $ 0.37
Diluted 0.33 0.03 0.25 0.36
1997: Basic 0.24 (0.60) 0.21 0.31
Diluted 0.23 (0.60) 0.20 0.31
- -----------------------------------------------------------------------------------------------------------------------------------
Market price per common share (New York Stock Exchange):
1998: High $ 37-7/16 $ 39-5/8 $ 46-1/2 $ 55-11/16
Low 31-1/16 33-3/8 36-3/8 42-1/16
1997: High 24 26-7/8 30 35
Low 19-1/2 22-1/8 25-7/16 27-5/16
- -----------------------------------------------------------------------------------------------------------------------------------
Dividends declared per common share:
1998 $ 0.0550 $ 0.0550 $ 0.0575 $ 0.0575
1997 0.0550 0.0550 0.0550 0.0550
- -----------------------------------------------------------------------------------------------------------------------------------
Number of registered common shareholders at year-end:
1998 10,500
===================================================================================================================================
</TABLE>
38
<PAGE>
Five Year Financial Summary
<TABLE>
<CAPTION>
===============================================================================================================================
In millions, except per share amounts 1998 1997 1996 1995 1994
- -------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
Results of operations:(3)
Net sales $15,273.6 $13,749.6 $11,831.6 $10,513.1 $9,469.1
Operating profit 772.2 261.4 591.9 271.7 416.8
Comparable operating profit(1) 940.5 779.1 604.7 486.8 416.8
Earnings from continuing operations before extraordinary item 396.4 76.5 372.4 83.4 185.9
Comparable earnings from continuing operations before
extraordinary item(2) 510.1 419.2 306.8 210.2 185.9
Net earnings (loss) 396.4 76.9 208.2 (547.1) 400.2
- -------------------------------------------------------------------------------------------------------------------------------
Per common share:
Earnings from continuing operations before extraordinary item:
Basic $ 0.99 $ 0.17 $ 0.98 $ 0.18 $ 0.47
Diluted 0.98 0.16 0.95 0.18 0.47
Comparable earnings from continuing operations before
extraordinary item:(2)
Basic 1.28 1.08 0.80 0.53 0.47
Diluted 1.26 1.05 0.78 0.53 0.47
Weighted average number of common shares outstanding used to
calculate comparable diluted earnings per common share 405.2 396.0 383.6 364.8 361.6
Cash dividends 0.225 0.220 0.220 0.760 0.760
- -------------------------------------------------------------------------------------------------------------------------------
Financial position and other data:
Total assets $ 6,763.2 $ 5,978.9 $ 6,014.9 $ 6,614.4 $7,202.9
Total long-term debt 275.7 290.4 1,204.8 1,056.3 1,012.3
Shareholders' equity 3,110.6 2,614.6 2,413.8 2,567.4 3,341.4
Depreciation and amortization 249.7 238.2 205.4 186.4 169.5
Number of stores 4,122 4,094 4,204 3,715 3,617
- -------------------------------------------------------------------------------------------------------------------------------
Percentage of net sales:
Operating profit 5.1% 1.9% 5.0% 2.6% 4.4%
Comparable operating profit(1) 6.2% 5.7% 5.1% 4.6% 4.4%
Earnings from continuing operations before extraordinary item 2.6% 0.6% 3.1% 0.8% 2.0%
Comparable earnings from continuing operations before
extraordinary item(2) 3.3% 3.0% 2.6% 2.0% 2.0%
Net earnings (loss) 2.6% 0.6% 1.8% (5.2%) 4.2%
===============================================================================================================================
</TABLE>
(1) Comparable operating profit excludes the pre-tax effect of the following
non-recurring charges: (i) in 1998, $158.3 million ($107.8 million
after-tax) related to the merger of CVS and Arbor and $10.0 million ($5.9
million after-tax) related to the markdown of non-compatible Arbor
merchandise, (ii) in 1997, $411.7 million ($273.7 million after-tax)
related to the merger of CVS and Revco, $75.0 million ($49.9 million
after-tax) related to the markdown of non-compatible Revco merchandise and
$31.0 million ($19.1 million after-tax) related to the restructuring of
Big B, Inc., (iii) in 1996, $12.8 million ($6.5 million after-tax) related
to the write-off of costs incurred in connection with the failed merger of
Rite Aid Corporation and Revco and (iv) in 1995, $165.5 million ($97.7
million after-tax) related to the Company's strategic restructuring
program and the early adoption of SFAS No. 121, and $49.5 million ($29.1
million after-tax) related to the Company changing its policy from
capitalizing internally developed software costs to expensing the costs as
incurred, outsourcing certain technology functions and retaining certain
employees until their respective job functions were transitioned.
(2) Comparable earnings from continuing operations before extraordinary item
and comparable earnings per common share from continuing operations before
extraordinary item exclude the after-tax effect of the charges discussed in
Note (1) above and a $121.4 million ($72.1 million after-tax) gain realized
during 1996 upon the sale of certain equity securities received from the
sale of Marshalls.
(3) Prior to the Mergers, Arbor's fiscal year ended on July 31 and Revco's
fiscal year ended on the Saturday closest to May 31. In recording the
business combinations, Arbor's and Revco's historical stand-alone
consolidated financial statements have been restated to a December 31
year-end, to conform with CVS' fiscal year-end. As permitted by the rules
and regulations of the Securities and Exchange Commission, Arbor's fiscal
year ended July 31, 1995 and Revco's fiscal year ended June 3, 1995 have
been combined with CVS' fiscal year ended December 31, 1994.
39
EXHIBIT 21
CVS CORPORATION
SUBSIDIARIES OF THE REGISTRANT
As of December 31, 1998, CVS Corporation had the following significant
subsidiaries:
CVS Center, Inc. (a New Hampshire corporation)
CVS Foreign, Inc. (a New York corporation)
CVS Pharmacy, Inc. (a Rhode Island corporation)
Nashua Hollis CVS, Inc. (a New Hampshire corporation)(1)
CVS Vanguard, Inc. (a Minnesota corporation)
CVS New York, Inc. (a New York corporation, formerly Melville Corporation)
CVS Revco D.S., Inc. (a Delaware corporation, formerly Revco D.S., Inc.)
Revco Discount Drug Centers, Inc. (a Michigan corporation)(2)
Hook-SupeRx, Inc. (a Delaware corporation)(3)
Big B, Inc. (an Alabama corporation)(4)
Arbor Drugs, Inc. (a Michigan corporation)(5)
PharmaCare Management Services, Inc. (a Delaware corporation)(6)
- -----------------
(1) Nashua Hollis CVS, Inc. is the immediate parent corporation of approximately
1,500 corporations that operate drugstores, all of which drugstores are in the
United States. CVS of DC and VA, Inc. (formerly Peoples Drug Stores, Inc.), a
Maryland corporation and a direct subsidiary of Nashua Hollis CVS, Inc., is, in
turn, the immediate parent of approximately 12 corporations that operate
drugstores, all of which drugstores are in the United States. ProCare Pharmacy,
Inc. (formerly Specialty Pharmacy, Inc.), a Rhode Island corporation and a
direct subsidiary of Nashua Hollis CVS, Inc., operates several apothecaries
focused on specialty pharmaceuticals, all of which apothecaries are in the
United States.
(2) Revco Discount Drug Centers, Inc. (a Michigan corporation) is the immediate
parent corporation of two corporations that operate drugstores, all of which
drugstores are in the United States. Revco Discount Drug Centers, Inc. (an Ohio
corporation), a direct subsidiary of Revco Discount Drug Centers, Inc. (a
Michigan corporation) is, in turn, the immediate parent corporation of one
corporation that operates drugstores, all of which drugstores are in the United
States.
(3) Hook-SupeRx, Inc. is the immediate parent corporation of one corporation
that operates drugstores, all of which drugstores are in the United States.
(4) Big B, Inc. is the immediate parent corporation of one corporation that
operates drugstores, all of which drugstores are in the United States.
(5) Arbor Drugs, Inc. is the immediate parent corporation of one corporation
that operates drugstores and is the majority owner of two corporations that
operate apothecaries, all of which drugstores or apothecaries are in the United
States.
(6) PharmaCare Management Services, Inc., the Registrant's prescription benefits
management subsidiary, is 95.8% owned by subsidiaries of the Registrant.
PharmaCare Management Services, Inc. is, in turn, the immediate parent
corporation of PharmaCare Direct, Inc., a mail order pharmacy corporation.
EXHIBIT 23
CONSENT OF INDEPENDENT AUDITORS
The Board of Directors and Shareholders
of CVS Corporation:
We consent to incorporation by reference in the Registration Statements
Numbers 333-49407, 33-40251, 333-34927, 333-28043, 33-17181, 2-97913, 2-77397
and 2-53766 on Form S-8 and 333-52055 on Form S-3 of CVS Corporation of our
report dated January 27, 1999, relating to the consolidated balance sheets of
CVS Corporation and subsidiaries as of December 31, 1998 and 1997, and the
related consolidated statement of operations, shareholders' equity and cash
flows for each of the years in the three-year period ended December 31, 1998,
which report is incorporated by reference in the December 31, 1998 annual report
on Form 10-K of CVS Corporation and to our report dated January 27, 1999 on the
related financial statement schedule, which report appears in the December 31,
1998 annual report on Form 10-K of CVS Corporation.
/s/ KPMG LLP
- ------------
KPMG LLP
Providence, Rhode Island
March 29, 1999
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
consolidated balance sheet and the consolidated statement of operations for the
year ended December 31, 1998 and is qualified in its entirety by reference to
such financial statements.
</LEGEND>
<MULTIPLIER> 1,000
<CURRENCY> U.S. Dollars
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-START> JAN-01-1998
<PERIOD-END> DEC-31-1998
<EXCHANGE-RATE> 1
<CASH> 180,800
<SECURITIES> 0
<RECEIVABLES> 690,100
<ALLOWANCES> 39,800
<INVENTORY> 3,190,200
<CURRENT-ASSETS> 4,349,200
<PP&E> 2,039,800
<DEPRECIATION> 688,600
<TOTAL-ASSETS> 6,736,200
<CURRENT-LIABILITIES> 3,183,300
<BONDS> 275,700
0
280,000
<COMMON> 4,000
<OTHER-SE> 2,826,600
<TOTAL-LIABILITY-AND-EQUITY> 6,736,200
<SALES> 15,273,600
<TOTAL-REVENUES> 15,273,600
<CGS> 11,144,400
<TOTAL-COSTS> 11,144,400
<OTHER-EXPENSES> 3,357,000
<LOSS-PROVISION> 6,300
<INTEREST-EXPENSE> 60,900
<INCOME-PRETAX> 711,300
<INCOME-TAX> 314,900
<INCOME-CONTINUING> 396,400
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 396,400
<EPS-PRIMARY> 0.99
<EPS-DILUTED> 0.98
</TABLE>
